curriculum vitae robert a. hauser, m.d., m.b.a.hsc.usf.edu/.../0/hausercv31405.pdfcurriculum vitae...
TRANSCRIPT
CURRICULUM VITAE
Robert A. Hauser, M.D., M.B.A. BUSINESS ADDRESS: HOME ADDRESS:
University of South Florida 2575 Regal River Road Parkinson’s Disease and Movement Disorders Center Valrico, Florida 33549 4 Columbia Drive, Suite 410 Tampa, Florida 33606 Phone: (813) 844-4077 Fax: (813) 844-4456
_____________________________
Robert A. Hauser, M.D., M.B.A. EDUCATION
B.A. Brandeis University 1978
Waltham, Massachusetts (Magna cum laude)
M.D. Temple University School of Medicine 1982
Philadelphia, Pennsylvania
M.B.A. University of South Florida 2000
Tampa, Florida
CERTIFICATIONS
Board Certified in Neurology By the American Board of Psychiatry and Neurology November, 1989 Certified in MRI By the American Society of Neuroimaging March, 1990
2
INTERNSHIP PGY-I Albert Einstein Medical Center 7/82-6/83 Philadelphia, Pennsylvania Surgery I
RESIDENCY
PGY-II, III Eastern Virginia Graduate School 7/83-6/85 of Medicine Norfolk General Hospital Norfolk, Virginia Neurosurgery I, II PGY-IV, V Eastern Virginia Graduate School 7/85-6/87 of Medicine
Norfolk General Hospital Norfolk, Virginia Neurology I, II PGY-VI Eastern Virginia Graduate School 7/87-6/88 of Medicine
Norfolk General Hospital Norfolk, Virginia Neurology III - Chief Resident in Neurology
Master of Business Administration (M.B.A)
University of South Florida 4/2000
3
POSITIONS HELD
Neurologist 7/88-12/88 Neurology Specialists Norfolk, Virginia Movement Disorders Fellow 1/89-6/90 With C.W. Olanow, M.D. University of South Florida Tampa, Florida Instructor 1/90-6/90 University of South Florida Tampa, Florida Assistant Professor of Neurology 7/90-6/96 University of South Florida Tampa, Florida Assistant Director 7/90-7/94 Movement Disorders Center University of South Florida Tampa, Florida Director 7/94-Present Parkinson’s Disease and Movement Disorders Center University of South Florida Tampa, Florida Chief 9/94-1/05 Section of Neurology Tampa General Hospital Tampa, Florida Co-Director 4/96-6/98 Neuro ICU Tampa General Healthcare Tampa, Florida Associate Professor of Neurology, 7/96- 7/01 Pharmacology and Experimental Therapeutics University of South Florida Tampa, Florida
Rotating Vice Chairman Department of Neurology University of South Florida Tampa, Florida 10/03-10/04
4
Professor of Neurology, 7/01 - Present Pharmacology and Experimental Therapeutics University of South Florida Tampa, Florida Medical Director 1/01 – Present Florida Coalition to Cure PD
5
MEMBERSHIPS
American Medical Association American Academy of Neurology American Society of Neuroimaging Movement Disorders Society Parkinson Study Group American Society of Neural Transplantation Huntington Study Group Fellow Member, American Academy of Neurology, 2004 – present
NATIONAL COMMITTEE MEMBERSHIPS AND SERVICE
Member, Executive Committee, American Academy of Neurology, Section on Interventional Neurology 1995-1999 Surgical Approaches Working Group, Huntington’s Study Group 1995-2004 Nominating Committee, Parkinson Study Group 1997 Nominating Committee, American Society of Neural Transplantation 1996-1997 Nominating Committee, American Academy of Neurology, Movement Disorders Section 1998-2000 Scientific Advisory Council, Huntington’s Disease Society of America 1998-2000 Nominating Committee, Parkinson Study Group 1999 Secretary, Executive Committee, American Academy of Neurology, Section on Interventional Neurology, 1999-2000 Nominating Committee, Huntington Study Group, 2000 Member, Executive Committee, American Academy of Neurology, Section on Movement Disorders 2001-present Vice Chairman, American Academy of Neurology, Section on Interventional Neurology, 2001-2003 Member, Center Program and Education Advisory Committee, Huntington’s Disease Society of America, 2001-2003 Chairman, American Academy of Neurology, Section on Interventional Neurology, 2003-present Executive Committee, Parkinson Study Group. 2004-present
6
LICENSES Florida 54906
7
MANUSCRIPTS 1. Hauser RA, Lacey DM, Knight MR. Hypertensive encephalopathy: magnetic resonance imaging demonstration of reversible cortical and white matter lesions. Arch Neurol 1988;45:1078-1083. 2. Rish BL, Hauser RA. Osteopetrosis: A review of a bone disease with neurological sequelae requiring surgical management. Neuro-Orthopedics 1988;5:112-118. 3. Hauser RA. Cerebral Hypoxia. Etiology, sequelae, and intervention. Resident and Staff Physician 1988;34(11):43-50. 4. Hauser RA, Olanow CW. Effective Parkinson’s treatment. An update on strategy. Senior patient. 1990;2:26-31. 5. Hauser RA, Olanow CW. Critical drug appraisal. Pergolide. Drug Therapy 1990;20;62-71. 6. Hauser RA, Alden SL, Coar DN, Cundiff MR, Bundshuh CC. Intramedullary spinal cord sarcoidosis mimicking glioma by magnetic resonance imaging. Paraplegia 1991;29:203-206. 7. Hauser RA, Olanow CW. Critical drug appraisal. Pergolide. P&T 1991;16(7):643-654. 8. Woodward WR, Olanow CW, Beckner RM, Hauser RA, Gauger LL, Cedarbaum JM, Nutt J. The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses. Neurology 1993;43:1704-1708. 9. Hauser RA, Olanow CW. Oro-buccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson’s disease. Movement Disorders 1993;8:512-514. 10. Griffin DK, Shriver ME, Hauser RA. Parinaud’s syndrome as the initial manifestation of acquired immunodeficiency syndrome. J Neuroimaging 1994;4:113-114. 11. Hauser RA, Olanow CW. Magnetic resonance imaging of neurodegenerative disorders. J Neuroimaging 1994;4:146-158. 12. Hauser RA, Trehan R. Initial experience with electroconvulsive therapy for progressive supranuclear palsy. Movement Disorders 1994;9:467-469. 13. Koller WC, Busenbark K, Miner K, and the Essential Tremor Study Group (including Hauser RA). The relationship of essential tremor to other movement disorders: Report on 678 patients. Ann Neurol 1994;35:717-723. 14. Hauser RA, Zesiewicz TA, Rosemurgy AS, Martinez C, Olanow CW. Manganese intoxication and chronic liver failure. Ann Neurol 1994;36:871-875. 15. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJG, Mufson EJ, Sanberg PR, Hauser RA, Smith DA, Nauert GM, Perl DP, Olanow CW. Neuropathological evidence of graft survival and striatal
8
reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. NEJM 1995;332:1118-24. 16. Hauser RA, Zesiewicz TA. Sertraline-induced exacerbation of tics in Tourette’s syndrome. Movement Disorders 1995;10:682-684. 17. Olanow CW, Hauser RA, Gauger LL, Malapira T, Koller W, Hubble J, Busenbark K, Lillienfeld D, Esterlitz J. The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 1995;38:771-777. 18. Freeman TB, Olanow CW, Hauser RA, Nauert GM, Smith DA, Borlongan CV, Sanberg PR, Holt DA, Kordower JH, Vingerhoets FJG, Snow BJ, Snow BA, Calne D, Gauger LL. Bilateral fetal nigral transplantation into the post commissural putamen in Parkinson’s disease. Annals of Neurology 1995;38:379-388. 19. Hauser RA, Zesiewicz TA, Martinez C, Rosemurgy AS, Olanow CW. Blood manganese correlates with brain magnetic resonance imaging changes in patients with liver disease. Canadian Journal of Neurological Sciences 1996;23:95-98. 20. Hauser RA, Murtagh FR, Akhter K, Gold M, Olanow CW. Magnetic resonance imaging of corticobasal degeneration. Journal of Neuroimaging 1996;6:222-226. 21. Borlongan CV, Freeman TB, Hauser RA, Cahill DW, Sanberg PR. Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism: relevance to neural transplantation. Surgical Neurology 1996;46:384-388. 22. Parkinson Study Group, Kieburtz K, primary author (including Hauser RA). Effect of lazabamide on the progression of disability in early Parkinson’s disease. Ann Neurol 1996;40:99-107. 23. Hauser RA, Zesiewicz TA. Manganese and liver disease. Movement Disorders 1996;11:589. 24. Block G, Liss C, Reines S, Irr J, Nibbelink D, and the CR First Study Group (including Hauser RA). Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease: A multicenter 5-year study. Eur Neurol 1997;37:23-27. 25. Hauser RA, Zesiewicz TA, Factor SA, Guttman M, Weiner WJ. Clinical trials of add-on medications in Parkinson’s disease: efficacy versus usefulness. Parkinsonism & Related Disorders 1997;3:1-6. 26. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease. Movement Disorders 1997;12:756-759. 27. Parkinson Study Group (including Hauser RA). Safety and efficacy of pramipexole in early Parkinson’s disease. A randomized dose-ranging study. JAMA 1997; 278:125-130. 28. Borlongan CV, Koutzouzis TK, Freeman TB, Hauser RA, Cahill DW, Sanberg PR. Hyperactivity and hypoactivity in a rat model of Huntington’s disease: the systemic 3-nitropropionic acid model. Brain Research Protocols 1997;1:253-257. 29. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O’Brien CF. Ropinirole for the treatment of early Parkinson’s disease. Neurology 1997;49:393-399.
9
30. Holt DA, Nauert GM, Othberg AI, Randall TS, Willing AE, Widen RH, Hauser RA, Sanberg PR, Olanow CW, Freeman TB. Infectious issues in human fetal neural transplantation. Cell Transplantation 1997;6:553-556. 31. Freeman TB, Vawter D, Goetz CG, Leaverton PE, Hauser RA, Sanberg PR, Godbold JH, Olanow CW. Toward the use of surgical placebo-controlled trials. Transplantation Proceedings1997;29:1925. 32. Koller W, Pahwa R, Busenbark K, Hubble J, Wilkinson S, Lang A, Tuite P, Sime E, Lazano A, Hauser R, Malapira T, Smith D, Tarsy D, Miyawaki E, Norregaard T, Kormos T, Olanow CW. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol 1997; 292-299. 33. Gold M, Hauser RA, Chen MF. Plasma thiamine deficiency associated with Alzheimer’s disease but not Parkinson’s disease. Metabolic Brain Disease 1998;13:43-53. 34. Hauser RA, Friedlander J, Smith DA, Nolan MF. Delayed stimulation-induced thalamic ataxia syndrome. Neurology 1998:50:1184-1185. 35. Kordower JH, Freeman TB, Chen EY, Mufson EJ, Sanberg PR, Hauser RA, Snow B, Olanow CW. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson’s disease. Movement Disorders 1998;13:383-393. 36. Hauser RA, Molho E, Shale H, Pedder S, Dorflinger EE, and the Tolcapone De Novo Study Group. A pilot evaluation of the tolerability, safety and efficacy of tolcapone alone, and in combination with oral selegiline, in untreated Parkinson’s disease patients. Movement Disorders 1998;13:643-647. 37. Hauser RA, Malek AR, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998;51:912-913. 38. Sethi KD, O’Brien CF, Hammerstad JP, Adler CH, Davis TL, Taylor RL, Sanchez-Ramos J, Bertoni JM, Hauser RA. Ropinirole for the treatment of early Parkinson’s disease: a 12-month experience. Arch Neurol 1998;55:1211-1216. 39. Adler CH, Singer C, O’Brien C, Hauser RA, Lew MF, Marek KL, Dorflinger E, Pedder S, Deptula D, Yoo K. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch Neurol 1998;55:1089-1095. 40. Kompoliti K, Goetz CG, Boeve BF, Maraganore DM, Ahlskog JE, Marsden CD, Bhatia KP, Greene PE, Przedborski S, Seal EC, Burns RS, Hauser RA, Gauger LL, Factor SA, Molho ES, Riley DE. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 1998;55:957-961. 41. Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, Olanow CW. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson’s disease. Arch Neurol 1999;56:179-187. 42. Zesiewicz TA, Gold M, Chari G, Hauser RA. Current issues in depression in Parkinson’s disease. Am J Geriatr Psych 1999;7:110-118.
10
43. Zesiewicz TA, Hauser RA. Ropinirole in the treatment of Parkinson’s disease. Expert Opinion on Investigational Drugs 1999;8:697-710. 44. Hauser RA, Zesiewicz TA. Management of early Parkinson’s disease. Medical Clinics of North America 1999;83:393-414. 45. Zesiewicz TA, Gold M, Chari G, Hauser RA. Depression and Anxiety in Parkinson’s Disease. American Journal of Geriatric Psychiatry. 1999;7:110-118. 46. Freeman TB, Vawter DE, Leaverton PE, Godbold JH, Hauser RA, Goetz CG, Olanow CW. Use of placebo surgery in controlled trials of cellular-based therapy for Parkinson’s disease. NEJM 1999; 341:988-992. 47. Hauser RA, Wahba MN, Zesiewicz TA, McDowell Anderson W. Modafinil treatment of pramipexole-associated somnolence. Mov Disord 2000;15:1269-1271. 48. Olanow CW, Tasmar Advisory Panel (including Hauser RA). Tolcapone and hepatotoxic effects. Arch Neurol 2000:57;263-267. 49. Zesiewicz TA, Hauser RA. Depression in patients with Parkinson's disease: epidemiology, pathophysiology and treatment options. CNS Drugs 2000;13:227-304. 50. Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O’Brien CF, Molho ES, Factor SA. A home diary to assess functional status in Parkinson’s disease patients with motor fluctuations and dyskinesia. Journal of Clinical Neuropharmacology 2000;23:75-81. 51. Zesiewicz TA, Helal M, Hauser RA. Sildenafil Citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Movement Disorders 2000;15:305-308. 52. Hauser RA, Freidlander J, Baker MJ, Thomas J, Zuckerman R. Adult Chediak-Higashi parkinsonian syndrome with dystonia. Movement Disorders 2000; 15:705-708. 53. Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow WC. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. Movement Disorders 2000;15:485-489. 54. Freeman TB, Hauser RA, Sanberg PR, Saporta S. Neural transplantation for the treatment of Huntington's disease. Progress in Brain Research 2000;127:405-11. 55. Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence and episodes of daytime sleep. Movement Disorders 2000;15:658-663. 56. Freeman TB, Cicchetti F, Hauser RA, Deacon TW, Li XJ, Hersch SM, Nauert GM, Sanberg PR, Kordower JH, Saporta S, Isacson O. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:13877-82. 57. Freeman TB, Hauser RA, Sanberg PR, Saporta S. Neural transplantation for the treatment of Huntington’s disease. Progress in Brain Research 2000;127:405-411.
11
58. Freeman TB, Hauser RA, Willing AE, Zigova T, Sanberg PR, Saporta S. Transplantation of human fetal striatal tissue in Huntington's disease: rationale for clinical studies. Novartis Foundation Symposium 2000;231:129-138; discussion 139-147. 59. Zesiewicz TA, Hauser RA. Depression in Parkinson’s Disease. CNS Drugs 2000. 60. Hauser RA, Wahba MN, Zesiewicz TA, Anderson WM. Modafinil treatment of pramipexole associated somnolence. Movement Disorders 2000;15:1269-1271. 61. Zesiewicz TA, Hauser RA. Neurosurgery for Parkinson's Disease. Seminars in Neurology 2001;21:91-101. 62. The Huntington Study Group (including Hauser RA). A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology 2001;57:397-404. 63. Zesiewicz TA, Hauser RA. Phenomenology and treatment of tremor disorders. Neurologic Clin 2001;19:3:651-680. 64. Zesiewicz TA, Baker MJ, Dunne PB, Hauser RA. Diffuse Lewy Body Disease. Current Treatment Options in Neurology 2001;6:507-518. 65. Parkinson Study Group (including Hauser RA). A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 2001;56:455-462. 66. Freeman TB, Willing A, Zigova T, Sanberg PR, Hauser RA. Neural transplantation in Parkinson’s disease. Advances in Neurology 2001;86:435-445. 67. Weiner WJ, Factor SA, Jankovic J, Hauser RA, Tetrud JW, Waters CH, Shulman LM, Glassman PM, Beck B, Paume D, Doyle C. The long-term safety and efficacy of pramipexole in advanced Parkinson’s disease. Parkinsonism and Related Disorders 2001;7(2)115-120. 68. Hauser RA, Burke D. Videotape demonstration of a sensory trick in writer’s cramp. Movement Disorders 2002;17:427. 69. Zesiewicz TA, Hauser RA. Depression in Parkinson’s disease. Curr Psychiatry Rep 2002;4:69-73. 70. Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, Scott D, Nauert GM, Soety E, Sossi V, Holt A, Sanberg PR, Stoessl AJ, Freeman TB. Bilateral human fetal striatal transplantation in Huntington’s disease. Neurology 2002;58:687-695. 71. Zesiewicz TA, Encarnacion E, Hauser RA. Management of essential tremor. Curr Neurol Neurosci Rep 2002;2:324-330. 72. Hauser RA, Holford NH. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson’s disease. Movement Disorders 2002;17:(5)961-968. 73. Zesiewicz TA, Borra S, Hauser RA. Clozapine withdrawal symptoms in a Parkinson’s disease patient. Movement Disorders 2002;17(6)1365-1367.
12
74. Zesiewicz TA, Cimino CR, Malek AR, Gardner N, Leaverton PL, Dunne PB, Hauser RA. Driving safety in Parkinson’s disease. Neurology 2002;59:(11)1787-1788. 75. Parkinson Study Group (including Hauser RA). A controlled trial of rasagiline in early Parkinson Disease. Arch Neurol 2002;59:1937-1943. 76. Zesiewicz TA, Baker MJ, Wahba M, Hauser RA. Autonomic nervous system dysfunction in Parkinson’s disease. Curr Treat Options Neurol 2003;5:149-160. 77. Zesiewicz TA, Hauser RA. Sleep attacks and dopamine agonists for Parkinson’s disease: What is currently known? CNS Drugs 2003;17:593-600. 78. Whone AL, Warrs RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol, July 2003,54(1)93-101. 79. Crawford FC, Ait-Ghezala G, Morris M, Sutcliffe MJ, Hauser RA, Silver AA, Mullan MJ. Translocation breakpoint in two unrelared Tourette syndrome cases, within a region previously linked to the disorder. Hum Genet 2003;113:154-161. 80. Kase H, Aoyama S, Ichimura M, Ikeda K, Ishii A, Kanda T, Koga K, Koike N, Kurokawa M, Kuwana Y, Mori A, Nakamura J, Nonaka H, Ochi M, Saki M, Shimada J, Shindou T, Shiozaki S, Suzuke F, Takeda M, Yanagawa K, Richardson PJ, Jenner P, Bedard P, Borrelli E, Hauser RA. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson’s disease. Neurology 2003, 61(Suppl 6):S97-100. 81. Hauser RA, Hubble JP, Truong DD, Istradefylline US-001 Study Group. Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303. 82. Zesiewicz TA, Carter SN, Sullivan KL, Staffeetti JS, Dunne PB, Hauser RA. Initial management of Parkinson’s disease in a Florida community. J Applied Research 2004;4:95-98. 83. Adler CH, Hauser RA, Sethi K, Caviness JN, Marlor L, Anderson M, Hentz JG. Ropinirole for Restless Legs Syndrome: A Placebo-Controlled Crossover Trial. Neurology 2004;62:1405-1407. 84. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM; Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study. Movement Disorders 2004;19:426-432. 85. Parkinson Study Group (including Hauser RA). A controlled, randomized, delayed-start study of rasagiline in early parkinson disease. Arch Neurol 2004; 61; 561-566. 86. Hauser RA. Levodopa/carbidopa/entacapone triple combination (Stalevo). Neurology 2004;62 (Suppl1):S64-71. 87. Zesiewicz TA, Strom JA, Borenstein AR, Hauser RA, Cimino CR, Fontanet H, Cintron C, Staffetti JF, Dunne PB, Sullivan KL. Heart failure in Parkinson's disease: analysis of the United States medicare current beneficiary survey. Parkinsonism Relat Disord 2004;10:417-420.
13
88. Zesiewicz TA, Louis ED, Sullivan KL, Menkin M, Dunne PB, Hauser RA. Substantial improvement in a Meige's syndrome patient with levetiracetam treatment. Movement Disorders 2004;19:1518-1521. 89. Zesiewicz TA, Stamey W, Sullivan KL, Hauser RA. Botulinum toxin A for the treatment of cervical dystonia. Expert Opin Pharmacother 2004;5:2017-2024. 90. Pahwa R, Lyons K, Hauser RA. Ropinirole therapy for Parkinson’s disease. Expert Review of Neurotherapeutics 2004;4:581-588. 91. Sullivan KL, Hauser RA, Zesiwicz TA. Essential tremor. Epidemiology, diagnosis, and treatment. Neurologist 2004;10:250-258. 92. Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, Olanow CW. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Movement Disorders 2004;19:916-923. 93. Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: further validation and implications for clinical trials. Movement Disorders 2004;19:1409-1413. 94. Hauser RA, Lyons K. Future treatments for Parkinson’s disease. Neurol Clin 2004;22(Suppl):S149-166. 95. Connors JJ 3rd, Sacks D, Furlan AJ, Selman WR, Russell EJ, Stieg PE, Hadley MN, Wojak JC, Koroshetz WJ, Heros RC, Strother CM, Duckwiler GR, Durham JD, Tomsick TO, Rosenwasser RH, McDougall CG, Haughton VM, Derdeyn CP, Wechsler LR, Hudgins PA, Alberts MJ, Raabe RD, Gomez CR, Cawley CM 3rd, Krol KL, Futrell N, Hauser RA, Frank JI. Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: a joint statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, the American Society of Neuroradiology, the Congress of Neurological Surgeons, the AANS/CNS Cerebrovascular Section, and the Society of Interventional Radiology. Neurology 2005;64:190-198. 96. Zesiewicz TA, Hauser RA, Louis ED, Sullivan KL, Elble R, Dewey R, Ondo W, Rajput A, Weiner WJ. Practice Parameter: Therapies for essential tremor (an evidence based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology (In Press).
14
ABSTRACTS 1. Brownson RH, Ridgeway SH, Hauser RA and Kline AW. Comparative cytoarchitecture of cerebral
cortex in odontocetes with special emphasis on symmetry. Anat Rec 1984;20:24A. 2. Brownson RH, Ridgeway SH, Hauser RA. Comparative cytoarchitecture of cerebral cortex in
odontocetes with special emphasis on symmetry. Anat Rec 1985;211:27A. 3. Brownson RH, Hauser RA. Comparative cytoarchitectonics of cerebral cortex in odontocetes with
special emphasis on laterality and age. In: Proceedings of the XII International Anatomical Congress, London, 1985;A79.
4. Hauser RA, Lacey MD, Knight MR. Hypertensive encephalopathy. MRI demonstration of reversible
cortical and white matter lesions. Neurology 1988;38(1):110. 5. Hauser RA, Olanow CW. Oro-buccal dyskinesia associated with trihexyphenidyl therapy in a patient
with Parkinson’s disease. Movement Disorders 1990;6(3):211. 6. Olanow CW, Woodward R, Hauser RA, et al. Central pharmacokinetics of levodopa + phenylalanine
in a patient with advanced Parkinson’s disease. Neurology 1992;42(4):420. 7. Korthals JK, Hauser RA, Olanow CW. Electromyographic studies on orthostatic tremor. Movement
Disorders 1992;7(1):45. 8. Hauser RA, Knisely SS. Reversible, non-enhancing MRI lesions in hypertensive encephalopathy.
Journal of Neuroimaging 1993;3:76-77. 9. Freeman TB, Hauser RA, Sanberg P, et al. Fetal transplantation in Parkinson’s disease. Neurology
1994;44(Suppl 2):A324. 10. Olanow CW, Koller WC, Hauser RA, et al. A prospective, longitudinal controlled study of deprenyl
in Parkinson’s disease. Neurology 1994;44(Suppl 2):A258. 11. Hauser RA, Olanow CW, Koller WC. Time course of wash-out of symptomatic medication in
Parkinson’s disease. Neurology 1994;44(Suppl 2);A259. 12. Hauser RA, Zesiewicz T, Olanow CW. Manganese overload may cause the clinical and magnetic
resonance imaging abnormalities of chronic liver disease. Movement Disorders 1994;9 (suppl 1):118. 13. Freeman TB, Hauser RA, Sandberg OR, Borlongan CV, Snow BJ, Vingerhoets FJG, Smith DA,
Olanow CW: Fetal tissue transplantation in Parksinon’s Disease. International Behavior Neuroscience Society 1994; 3:22
14. Freeman TB, Olanow CW, Hauser RA, et al. Fetal nigral transplantation into the postcommissural
putamen in Parkinson’s disease: The USF experience. Journal of Neurosurgery 1995;82:354A.
15
15. Hauser RA, Zesiewicz TA, Martinez C, Rosemurgy AS, Olanow CW. Manganese intoxication may cause neurologic dysfunction in chronic liver disease. Neurology 1995;45 (S4):A369-370.
16. Hauser RA, Freeman TB, Gauger LL, Olanow CW. Fetal nigral transplantation for Parkinson’s
Disease. Fourth International Congress of Movement Disorders. Movement Disorders 1996;2(S1):249 17. Snow BJ, Vingerhoets FJG, Hauser RA, Freeman TB, Olanow CW. PET studies of bilateral fetal
nigral transplantation for Parkinson’s Disease. Fourth International Congress of Movement Disorders. Movement Disorders 1996;2(S1):250.
18. Hauser RA, Dorflinger E, Pedder S, Shimoun G, Yoo K, Molho E, Shale H, and the Tolcapone de
Novo Study Group. Tolerability and efficacy of tolcapone (Tasmar) in untreated Parkinson’s Disease (PD). Fourth International Congress of Movement Disorders. Movement Disorders 1996;S2:147.
19. Freeman TB, Vawter D, Goetz CG, Leaverton PE, Hauser RA, Sanberg PR, Godbold JH, Olanow
CW. Toward the use of surgical placebo-controlled trials. Transplantation Proceedings 1997;29:1925. 20. Hauser RA, Freeman TB, Snow BJ, Sanberg PR, Nauert GM, Borlongan CV, Kordower JH, Olanow
CW. Fetal nigral transplantation for Parkinson’s disease: 12 - 24 month evaluation. In Press Experimental Neurology
21. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease.
Movement Disorders 1996;5:603. 22. Borlongan CV, Koutouzis TK, Poulos S, Saporta S, Hauser RA, Cahill DW, Freeman TB, Sanberg
PR. Bilateral intrastriatal transplantation of rat fetal striatal tissue into the 3-nitropropionic acid rat model of Huntington’s disease. Society for Neuroscience 1996;22:580.
23. Hauser RA, Freeman TB, Sanberg PR, Snow BJ, Nauert GM, Borlongan CV, Kordower JH, Olanow
CW. Fetal nigral transplantation for Parkinson’s disease. Cell Transplantation 1996;5:80. 24. Freeman TB, Vawter D, Goetz CG, Hauser RA, Kordower JH, Sanberg PR, Snow BJ, Olanow CW.
The use of cosmetic surgical placebo controlled trials. Cell Transplantation 1996;5:79. 25. Sanberg PR, Borlongan CV, Saporta S, Anton A, Hauser RA, Freeman TB, Cameron DF.
Transplantation of testis-derived sertoli cells into the brain. Cell Transplantation 1996;5:39. 26. Freeman TB, Kordower JH, Rosenstein J, Collier T, Burke M, Chen E-R, Li JM, Levey A, Mufson E,
Hauser RA, Snow BJ, Sandberg PR, Borlongan CV, Randall T, & Olanow CW: Survival of functional fetal nigral grafts in two patients with Parksinon’s disease. Journal of Neurosurgery 1997; 86:380A.
27. Kompoliti K, Goetz C, Maraganore DM, Boeve BF, Marsden CD, Bhatia KP, Greene PE,
Przedborski S, Seal ECJ, Burns RS, Hauser RA, Gauger L, Factor SA, Molho ES, Riley DE. Clinical presentation and pharmacological therapy in cortico-basal ganglionic degeneration. Ann Neurol 1996;40:534.
28. Freeman TB, Kordower JH, Hauser RA, Snow BJ, Sandberg PR, Olanow CW: Reasons for limited
clinical benefit following fetal nigral transplantation in the treatment of Parkinson’s disease. Society for Neuroscience Abstracts 1996; 26:248.
16
29. Chari G, Hauser RA. Prolonged isolated limb dystonia as the initial manifestation of corticobasal
degeneration. Movement Disorders 1997;12:41. 30. Smith DA, Hauser RA, Friedlander J, Malapira TJ, Nolan MF. Stimulation induced thalamic ataxia
syndrome. Neurology 1997;48:A432. 31. Zesiewicz TA, Naidu KA, Baker M, Pedregal A, Prockop L, Hauser RA. Effect of amitriptyline,
fluoxetine, and sertraline on dopamine concentration in rat striatum. Movement Disorders 1997;12:840.
32. Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O’Brien CF, Molho ES, Factor
SA. Evaluation of a new home diary to assess functional status in Parkinson’s disease patients with fluctuations and dyskinesia. Movement Disorders 1997;12:843.
33. Hauser RA, Zesiewicz TA, Friedlander J, Seeberger LC, O’Brien CF, Adler CH, Molho ES, Factor
SA. Impact of different severities of dyskinesia on patient-defined functional status in Parkinson’s disease. Movement Disorders 1997;12:843.
34. Hauser RA, Anderson WMcD, Friedlander J, Zesiewicz TA, Gauger LL. Somnolence associated
with pramipexole therapy in Parkinson’s disease. Movement Disorders 1997;12:845. 35. Damiano AM, Willian MK, Burch G, Hauser R, Weiner W, Means E. Patient and caregiver health-
related quality-of-life questionnaires for Parkinson’s disease: self-administration versus telephone interview. Quality of Life Research 1998;7:585.
36. Hauser RA, Stern MB, Olanow CW, Ferzola N, Azzaro A, Sharoky M. Tolerability and safety of
transdermal selegiline in mild to moderate Parkinson’s disease. Movement Disorders 1998;13(Suppl 2):256.
37. Brashear A, Truong D, Charles D, Comella C, Hauser RA, Tsui J, Botox Study Group, Branin MJ,
Mordaunt J, Gibson J, Nordquist M, Stagg A, Jenkins S. A randomized double-blind, placebo-controlled study of intramuscular Botox for the treatment of cervical dystonia. Movement Disorders 1998;13(Suppl 2):276.
38. O’Brien C, Hauser RA, Sutton JP, Brashear A, Botox Study Group, Ripp K, Mourdant J, Bugarin D,
Stagg A, Jenkins S. Evaluation of Botox manufactured from a new bulk toxin in the open label treatment of cervical dystonia. Movement Disorders 1998;13(Suppl 2):275.
39. Zesiewicz TA, Hauser RA, Helal M. Sildenafil citrate (Viagra) for the treatment of erectile
dysfunction in men with Parkinson’s disease. Neurology 1999;52(Suppl 2):A215-216. 40. Wendell CM, Hauser RA, Nagaria MH, Sanchez-Ramos JR, Zesiewicz TA. Chief complaints of
patients with Parkinson’s disease. Neurology 1999;52(Suppl 2):A90-91. 41. Factor SA, Weiner WJ, Jankovic J, Hauser RA, Tetrud JW, Waters CH, Shulman LM, Glassman
PM, Besck B, Paume D, Doyle C, and the Pramipexole Study Group. Four year safety and adverse events in an open-label experience of 306 patients on pramipexole for Parkinson’s disease. Neurology 1999;52(Suppl 2):A407-408.
17
42. 42. Weiner WJ, Factor SA, Jankovic J, Hauser RA, Tetrud JW, Waters CH, Shulman LM, Glassman PM, Besck B, Paume D, Doyle C, and the Pramipexole Study Group. The long-term safety and efficacy of pramipexole in advanced Parkinson’s disease. Neurology 1999;52(Suppl 2):A261-262.
43. Freeman T, Deacon T, Cicchette F, Hauser R, Sanberg P, Kordower JH, Saporta S, Isacson O.
Histological evaluation of human fetal striatal transplants in a patient with Huntington’s disease. American Society for Neural Transplantation and Repair Abstracts 1999;56:21.
44. Hauser RA, Comella C, Brashear A, Truong D, Charles PD, Tsui J, Botox 140-8051 Study Group,
Mordaunt J, Nordquist M, Bugarin D. A randomized, multicenter, double-blind, placebo-controlled study of original Botox (botulinum type A) purified neurotoxin complex for the treatment of cervical dystonia. Movement Disorders 1999; 56.
45. Hauser RA, Stoessl JA, Eichler SR, Schwartz SW, Sanberg PR, Saporta S, Nauert M, Randall T,
Hahn MA, Scott DL, Freeman TB. Pilot evaluation of human fetal striatal transplantation in Huntington disease. Neurology 2000; 54: (Suppl 3) S25.002
46. Zesiewicz TA, Cimino CR, Gardner NM, Leaverton P, Hauser RA. Driving Safety in Parkinson’s
Disease. Neurology 2000;54:S80.005. 47. Hauser RA, Wahba MN, Zesiewicz TA Modafinil treatment of pramipexole-induced somnolence.
Movement Disorders 2000;15:P680. 48. Hauser RA, Reider C, Stacey M, Hubble J, Seeberger L, Williamson K, Dingmann C, Rice R,
Krulewicz S, Zaninelli R. Acute versus gradual pramipexole to ropinirole switch. Movement Disorders 2000; 15: P681.
49. Hauser RA, Watts RL, Freeman TB, Bakay RA, Ellias SA, Stoessl AJ, Eidelberg D, Dinsmore JH,
Fink JS. A double-blind, randomized, controlled, multicenter clinical trial of the safety and efficacy of transplanted fetal porcine ventral mesencephalic cells versus imitation surgery in patients with Parkinson’s disease. Movement Disorders 2001;16:983-984.
50. Zesiewicz TA, Patel A, Cimino CR, Leaverton P, Staffeti JF, Hauser RA. Analysis of United States
Social Security disability insurance in Parkinson’s disease patient’s, 1999. Neurology 2001;56 (Suppl 3): A101.
51. Hubble J, Hauser RA, and the Kyowa 6002-US-001 Study Group. A novel adenosine antagonist
(KW-6002) as a treatment for advanced parkinson’s disease with motor complications. Neurology 2002;58(Suppl 3):A162.
52. Hauser RA, Zesiewicz TA, Delgado HM, Gauger LL, Feldman NT. Evaluation and treatment of fatigue in Parkinson’s disease. Neurology 2002;58 (Suppl 3):A433. 53. Zesiewicz TA, Hauser RA, Graves AB, Cimino CR, Staffetti JF, Dunne PB, Sullivan KL. Heart
failure in elderly parkinson’s disease patient’s: analysis of United States Medicare data, 1997- 1999. Neurology 2003;60 (Suppl 1): A83.
54. Adler CH, Hauser RA, Sethi K, Caviness JN, Marlor L, Hentz GH. Ropinirole is beneficial for restless legs syndrome: a placebo-controlled crossover trial. Neurology 2003;60
(Suppl 1):A439-440.
18
55. Zhigao Z, de la Fuente-Fernandez, Hauser RA, Freeman TB, Olanow CW, Stoessl JA
Dopaminergic alteration in Parkinson’s patients with off-period dyskinesia following striatal embryonic mesencephalic transplant. Neurology 2003;60 (Suppl 1): A126.
19
BOOK CHAPTERS
1. Olanow CW, Hauser RA. The treatment of early Parkinson’s disease. In: Marsden CD and Fahn S, eds. New Trends in Clinical Neurology; The Assessment and Therapy of Parkinsonism. England: Parthenon Publishing, 1990:77-88.
2. Hauser RA, Olanow CW. Considerations in the design of clinical trials in Parkinson’s disease.
In: Rose Clifford F, ed. Methodological Problems of Clinical Trials in Parkinson’s Disease. London: Smith-Gordon and Company, 1992:1-10.
3. Hauser RA, Olanow CW. Designing clinical trials in Parkinson’s disease. In: Olanow CW,
Lieberman, eds. The Scientific Basis for the Treatment of Parkinson’s Disease. London: Parthenon Publishers, 1992:275-293.
4. Hauser RA, Olanow CW. Parkinson’s disease in the elderly. In: Barclay L, ed. Clinical Geriatric
Neurology. Pennsylvania: Lea & Febiger 1993:155-169.
5. Olanow CW, Hauser RA. Recent advances in Parkinson’s disease. In: Appel S, ed. Current Neurology. Illinois: Mosby-Year Book Inc. 1993;12:111-154.
6. Olanow CW, Hauser RA. Neural transplants in the treatment of Parkinson’s disease and other
neurodegenerative disorders. In: Jankovic J, Tolosa, eds. Parkinson’s Disease and Movement Disorders. Maryland: Williams & Wilkins. 1993:549-568.
7. Hauser RA, Olanow CW. Magnetic resonance imaging in neurodegenerative diseases. In: Calne
DB, ed. Neurodegenerative Diseases. Pennsylvania: W.B. Saunders Co. 1994:445-469.
8. Hauser RA, Freeman TB, Olanow CW. Surgical therapy for Parkinson’s disease. In: Kurlan R, ed. Treatment of Movement Disorders. New York: J.B. Lippencott Co. 1995:57-93.
9. Freeman TB, Olanow CW, Hauser RA, Kordower JH, Holt DA, Borlongan CV, Sandberg PR.
Human fetal tissue transplantation. In: Germano IM, ed. Neurosurgical Treatment of Movement Disorders. Park Ridge, Illinois: American Association of Neurological Surgeons 1998:177-192.
10. Hauser RA, Olanow CW, Snow BJ, Freeman TB. Fetal nigral transplantation in Parkinson’s
disease: the USF pilot program (12- to 24-month evaluation). In Freeman TB, Widner H, eds. Cell Transplantation for Neurological Disorders: Toward Reconstruction of the Human Central Nervous System. Totowa, New Jersey: Humana Press Inc. 1998:19-30.
11. Hauser RA, Freeman TB. Surgical therapy of Parkinson’s disease. In: Sawle G, ed. Movement
Disorders in Clinical Practice. Isis Medical Media. 1999:57-71.
12. Hauser RA, Zesiewicz TA. Management of Parkinson’s disease in the elderly. In: Meara J, Koller W, eds. Parkinson’s Disease and Parkinson’s Syndrome in the Elderly. United Kingdom: Cambridge University Press. 2000;134-164.
20
13. Freeman TB, Hauser RA, Willing AE, Zigova T, Sanberg PR, Saporta S. Transplantation of human fetal striatal tissue in Huntington’s disease: rationale for clinical studies. In: Neural transplantation in neurodegenerative disease: current status and new directions. West Sussex, England: John Wiley & Sons. (Novartis Foundation Symposium 231). 2000:129-144.
14. Freeman TB, Hauser RA, Sanberg PR, Saporta S. Neural transplantation for the treatment of
Huntington’s disease. In: Dunnett SB, Bjorklund A, eds. Progress in Brain Research. Elsevier Science. 2000;127:405-411.
15. Encarnacion EV, Hauser RA. Neural transplantation in Parkinson’s disease. In: Pahwa R, ed.
Handbook of Parkinson’s Disease. Marcel Dekker, Inc. 2001:527-550.
16. Zesiewicz TA, Hauser RA. Monoamine oxidase inhibitors. In Factor SA, Weiner WJ, eds. Parkinson's Disease: Diagnosis and Clinical Management. New York: Demos Press. 2002:365-378.
17. Hauser RA, Zesiewicz T. Cell Transplantation. In: Pahwa R, Lyons K, eds. Therapy of
Parkinson’s Disease, Third Edition. New York City: Marcel Dekker. 2004:343-351.
18. Wahba M, Zesiewicz T, Hauser RA. Catechol-O-Methyltransferase Inhibitors in the Treatment of Parkinson’s Disease. In: Ebadi M and Pfieffer R, eds. Parkinson’s Disease. Boca Raton, Florida: CRC Press. 2005:(55)705-712.
19. Carlucci C, Hauser RA. Sleep apnea and Parkinson’s disease. In Pfeiffer R, ed. Parkinson’s
Disease and Non-Motor Dysfunction. (In Press). 20. Seeberger LC, Hauser RA. Cerebellar Tremor. In Lyons KE, Pahwa R, eds. Handbook of
Essential Tremor and Other Tremor Disorders. Taylor and Francis Group: Boca Raton, Florida, 2005.
21
BOOKS Hauser RA, Zesiewicz TA. Parkinson’s Disease: Questions and Answers. Merit Publishing, London 1996. Hauser RA, Zesiewicz TA. Parkinson’s Disease: Questions and Answers. Second Edition. Merit Publishing, London 1997. Hauser RA, Zesiewicz TA. Parkinson’s Disease: Questions and Answers. Third Edition. Merit Publishing, London 2000. Hauser RA, Pahwa R, Lyons K, Zesiewicz TA, Golbe L. Parkinson’s Disease: Questions and Answers. Fourth Edition. Merit Publishing, London 2003. EDITOR Hauser RA. Quality of Life in Parkinson's disease: Current findings with COMT inhibitors. Neurology Reviews (suppl) 2000. Hauser RA, Pahwa R, eds. Current Treatment Challenges and Emerging Therapies in Parkinson’s Disease. Philadelphia, Pa: W.B. Saunders Company. Neurologic Clinics 2004:22(3S). BOOK REVIEWS Hauser RA. Parkinson’s Disease: The Treatment Options. Lewitt PA, Oertel WH, eds. In NEJM 1999;341:1159. Hauser RA. A Life Shaken: My Encounter with Parkinson’s Disease. Joel Havemann. In JAMA 2002;288:2337. LETTERS Hauser RA, Olanow CW. Early therapy for Parkinson’s disease. Arch Neurol. 1991;48:1009-1010. Hauser RA, Zesiewicz TA. Manganese and chronic liver disease. Movement Disorders 1996;11:589. Borlongan CV, Polgar S, Freeman TB, Hauser RA, Cahill DW, Sanberg PR. Will fetal striatal transplants correct the akinetic end-stage of Huntington’s disease? Neurodegeneration 1996;5:189-192. Freeman TB, Hauser RA, Sanberg PR. Fatal transplant cyst. J Neurosurg 1999;90:1148-50.
22
Hauser RA, Sanberg PR, Freeman TB, Stoessl AJ. Bilateral human fetal striatal transplantation in Huntington’s disease. Neurology 2002;58:1704. RESPONSES TO LETTERS Hauser RA, Wahba MN, Zesiewicz TA, Anderson WM. Modafinil and pramipexole-assoiated somnolence. Movement Disorders 2001;16:783-784.
23
INTERNET PUBLICATIONS Hauser RA. Cell Transplantation for the Treatment of Parkinson’s Disease. Awakenings.com 1997. Hauser RA, Hubble JP, Richardson E. Parkinson’s Disease. www.Neuroscience.com. Perspectives on Current Issues in Neurology and Psychiatry. No. 5, May 1999. Hauser RA, Pahwa R. Parkinson’s disease. www.emedicine.com. 2000. Hauser RA, Burke D. Essential Tremor. www.emedicine.com. 2000. Hauser RA, Wahba MN. Cosmetic use of Botulinum Toxin. www.emedicine.com. 2000 Hauser RA. Neurotransplantation Strategies in Parkinson’s Disease. www.yourdoctor.com 2001 Hauser RA, New Therapeutic Approaches for Parkinson’s Disease. www.medscape.com/viewarticle/477724 2004. INTERNET EDITOR Movement Disorders Medical Editor for Neurology online textbook emedicine.com 2000- COMMUNITY PUBLICATIONS Hauser RA. Botulinum toxin: a new treatment for spasticity. National Multiple Sclerosis Society. Outlook 1997; May/June:9-10. EDITORIAL BOARD Movement Disorders 1999-2004
24
JOURNAL REVIEWER Neurology Movement Disorders Parkinsonism and Related Disorders Journal of Neuroimaging Cell Transplantation Journal of Clinical Neuropharmacology Lancet Clinical Pharmacology and Therapeutics GRANT REVIEWER Medical Research Council (MRC) of the UK The Wellcome Trust AWARDS AND HONORS Clinician/Scholar of the Year, USF Department of Neurology, 1995/1996
Faculty Scholar-Scientist Award, USF Department of Neurology 1998
Phi Kappa Phi National Honor Society
Beta Gamma Sigma National Honor Society
Best Doctors in America 2001-2002
Best Doctors in America 2002-2003
Best Doctors in Amnerica 2003-2004
Best Doctors in Amnerica 2004-2005
SCIENTIFIC COMMENTATOR WebMD 2000-
Lancet 2000-
25
NATIONAL AND INTERNATIONAL SCIENTIFIC PRESENTATIONS
1. Hauser RA. Hypertensive Encephalopathy. MRI demonstration of reversible cortical and white matter lesions. Poster Presentation. American Academy of Neurology 40th Annual Meeting, Chicago, Illinois, April 1988.
2. Hauser RA, Knisely SS. Reversible, non-enhancing MRI lesions in hypertensive
encephalopathy. Poster Presentation. American Society of Neuroimaging, 16th Annual Meeting. Orlando, Florida, February 4, 1993.
3. Hauser RA, Olanow CW, Koller WC. Time Course of Wash-out of Symptomatic Medication in
Parkinson’s Disease. Platform Presentation. American Academy of Neurology, 46th Annual Meeting, Washington D.C. May 3, 1994.
4. Hauser RA, Zesiewicz T, Olanow CW. Manganese Overload May Cause the Clinical and Magnetic Resonance Imaging Abnormalities of Chronic Liver Disease. Poster Presentation. Third International Congress of Movement Disorders. Orlando, Florida. November 9, 1994.
5. Hauser RA, Zesiewicz TA, Martinez C, Rosemurgy AS, Olanow CW. Manganese Intoxication
May Cause Neurologic Dysfunction in Chronic Liver Disease. Poster Presentation. 47th Annual Meeting of the American Academy of Neurology. Seattle, Washington. May 11, 1995.
6. Hauser RA, Freeman TB, Snow BJ, Sanberg PR, Nauert GM, Borlongan CV, Kordower JH,
Olanow CW. Fetal nigral transplantation for Parkinson’s disease: 12 - 24 month evaluation. Platform presentation. American Society of Neural Transplantation, third annual conference. Clearwater, Florida, April 25, 1996.
7. Hauser RA, Dorflinger E, Pedder S, Shimoun G, Yoo K, Molho E, Shale H, and the Tolcapone
de Novo Study Group. Tolerability and efficacy of tolcapone (Tasmar) in untreated Parkinson’s Disease (PD). Poster Presentation. Fourth International Congress of Movement Disorders. Vienna, Austria, June 17-21, 1996.
8. Hauser RA, Freeman TB, Gauger LL, Olanow CW. Fetal nigral transplantation for Parkinson’s
Disease. Poster Presentation. Fourth International Congress of Movement Disorders. Vienna, Austria, June 17-21, 1996.
9. Hauser RA, Freeman TB, Sanberg PR, Snow BJ, Nauert GM, Borlongan CV, Kordower JH,
Olanow CW. Fetal nigral transplantation for Parkinson’s disease. Platform Presentation. Third International Congress of the Cell Transplant Society. Miami, FL, October 2, 1996.
10. Chari G, Hauser RA. Prolonged isolated limb dystonia as the initial manifestation of corticobasal
degeneration. Poster Presentation. Third International Dystonia Symposium. Miami, FL, October 11, 1996.
11. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease.
Poster Presentation. Tenth annual symposia on Etiology, Pathogenesis, and Prevention of Parkinson’s disease. Miami, FL, October 13, 1996.
26
12. Smith DA, Hauser RA, Friedlander J, Malapira TJ, Nolan MF. Stimulation induced thalamic ataxia syndrome. Poster Presentation. 49th Annual Meeting of the American Academy of Neurology. Boston, MA, April 17, 1997.
13. Zesiewicz TA, Naidu KA, Baker M, Pedregal A, Prockop L, Hauser RA. Effect of amitriptyline,
fluoxetine, and sertraline on dopamine concentration in rat striatum. Poster Presentation. Eleventh Annual Symposia on Etiology, Pathogenesis, and Prevention of Parkinson’s disease and Hyperkinetic Movement Disorders. San Diego, CA, September 28, 1997.
14. Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O’Brien CF, Molho ES,
Factor SA. Evaluation of a new home diary to assess functional status in Parkinson’s disease patients with fluctuations and dyskinesia. Poster Presentation. Eleventh Annual Symposia on Etiology, Pathogenesis, and Prevention of Parkinson’s disease and Hyperkinetic Movement Disorders. San Diego, CA, September 28, 1997.
15. Hauser RA, Zesiewicz TA, Friedlander J, Seeberger LC, O’Brien CF, Adler CH, Molho ES,
Factor SA. Impact of different severities of dyskinesia on patient-defined functional status in Parkinson’s disease. Poster Presentation. Eleventh Annual Symposia on Etiology, Pathogenesis, and Prevention of Parkinson’s disease and Hyperkinetic Movement Disorders. San Diego, CA, September 28, 1997.
16. Hauser RA, Anderson WMcD, Friedlander J, Zesiewicz TA, Gauger LL. Somnolence associated
with pramipexole therapy in Parkinson’s disease. Poster Presentation. Eleventh Annual Symposia on Etiology, Pathogenesis, and Prevention of Parkinson’s disease and Hyperkinetic Movement Disorders. San Diego, CA, September 28, 1997.
17. Hauser RA, Stern MB, Olanow CW, Ferzola N, Azzaro A, Sharoky M. Tolerability and safety of
transdermal selegiline in mild to moderate Parkinson’s disease. Movement Disorders 1998;13(Suppl 2):256. Poster Presentation. Fifth International Congress of Movement Disorders. New York, NY. October 13, 1998.
18. Wendell CM, Hauser RA, Nagaria MH, Sanchez-Ramos JR, Zesiewicz TA. Chief complaints of
patients with Parkinson’s disease. Platform Presentation by Hauser RA. 51st Annual Meeting of the American Academy of Neurology. Toronto, Ontario, Canada. April 20, 1999.
19. Hauser RA, Stoessl JA, Eichler SR, Schwartz SW, Sanberg PR, Saporta S, Nauert M, Randall T,
Hahn MA, Scott DL, Freeman TB. Pilot evaluation of human fetal striatal transplantation in Huntington disease. Platform Presentation by Hauser RA. 52nd Annual Meeting of the American Academy of Neurology. San Diego, California. May 5, 2000.
20. Hauser RA, Wahba MN, Zesiewicz TA. Modafinil treatment of pramipexole-induced
somnolence. Poster Presentation by Hauser RA. 6th International Congress of Parkinson’s Disease and Movement Disorders. Barcelona, Spain. June 3, 2000.
21. Hauser RA, Reider C, Stacey M, Hubble J, Seeberger L, Gauger L, Williamson K, Dingmann C,
Rice R, Krulewicz S, Zaninelli R. Acute versus gradual pramipexole to ropinirole switch. Poster Presentation by Hauser RA. 6th International Congress of Parkinson’s Disease and Movement Disorders. Barcelona, Spain. June 3, 2000.
27
22. Hauser RA, Watts RL, Freeman TB, Bakay RA, Stoessl AJ, Eidelberg D, Dinsmore JH, Fink JS. A double-blind, randomized, controlled, multicenter clinical trial of the safety and efficacy of transplanted fetal porcine ventral mesencephalic cells versus imitation surgery in patients with Parkinson’s disease. Platform Presentation by Hauser RA. Fifteenth Annual Symposia on Etiology, Pathogenesis, and Prevention of Parkinson’s disease and Hyperkinetic Movement Disorders. Chicago, Illinois. September 30, 2001.
23. Hubble JP, Hauser RA, and the Kyowa 6002-US-001 Study Group. A novel adenosine
antagonist (KW-6002) as a treatment for advanced parkinson’s disease with motor complications. Platform Presentation by Hauser RA. 54th Annual meeting of the American Academy of Neurology. Denver Colorado. April 16, 2002.
24. Hauser RA, Zesiewicz TA, Delgado HM, Gauger LL, Feldman NT. Evaluation and treatment of
fatigue in Parkinson’s disease. Poster Presentation by Hauser RA. 54th Annual meeting of the American Academy of Neurology. Denver Colorado. April 18, 2002.
25. Hauser RA and the Parkinson Study Group. Early treatment with rasagiline may attenuate
progression of Parkinson’s disease. Platform Presentation by Hauser RA. 6TH Annual Congress of the European Federation of Neurological Societies. Vienna, Austria. October 27, 2002.
26. Hauser RA. Medical management of Early Parkinson’s disease. 15th annual scientific meeting of the Hong Kong Neurological Society. Hong Kong. November 18th 2002.
27. Hauser RA. Medical management of Advance Parkinson’s disease. 15th annual scientific
meeting of the Hong Kong Neurological Society. Hong Kong. November 18th 2002.
28. Hauser RA. The Role of Levodopa/carbidopa/entacapone Combination Treatment for Parkinson’s Disease. Optimizing Levodopa Therapy. Seville, Spain. May 6, 2003. 29. Hauser RA . Co-Chair (with Niall Quinn), Improving the Recognition of Wearing-off in Parkinson’s Disease. Seville, Spain. May 7, 2003.
30. Hauser RA. Practical Applications and Clinical Experience. Optimizing levodopa therapy: The role of COMT inhibition. EFNS Congress. Helsinki, Finland. Aug. 31, 2003.
31. Hauser RA. COMT Inhibitors in the Treatment of Parkinson’s Disease. Movement
Disorder Society 8th International Congress of Parkinson’s Disease and Movement Disorders. Rome, Italy. June 13, 2004.
32. Hauser RA. Overview of Clinical Trials Aimed at Detecting Disease Progression in
Parkinson’s Disease. New Approaches to Neuroprotective Therapy in Parkinson’s Disease. Hamilton, Bermuda. August 20, 2004.
33. Hauser RA. Does early treatment of Parkinson’s disease make a difference in the long
term? Platform presentation by Hauser RA. 8th Congress of the European Federation of Neurological Societies. Paris, France. September 5, 2004.
28
34. Hauser RA. Stalevo in Daily Practice – when, where and how? Platform presentation by Hauser RA. 8th Congress of the European Federation of Neurological Sociaties. Paris, France. September 5, 2004.
35. Hauser RA. Co-chairman, 2004 Wearing Off Working Group Meeting, Frankfurt,
Germany. September 16-17, 2004.
36. Hauser RA. Optimal use of a home diary in Parkinson’s disease clinical trials. Investigator Meeting Protocol 6002-EU-007. Montreux, Switzerland. October 1-2, 2004.
29
NATIONAL COURSES TAUGHT
1. Stroke: Etiology, Evaluation, Current and Future Therapies. American College of Physicians MKSAP VIII Review Course, Orlando, Florida, August 1990.
2. Parkinson’s Disease: Update on Treatment. The American College of Physicians MKSAP VIII
Review Course, Orlando, Florida, August 1990.
3. Magnetic Resonance Imaging of Parkinson’s Disease and Other Movement Disorders. American Society of Neuroimaging, 14th Annual Meeting. Orlando, Florida. February 6, 1991.
4. Neurology Review. MKSAP Annual Review Course. Orlando, Florida. August 1, 1993
5. Botulinum Toxin: Pharmacology Preparation & Side Effects. 57th Annual Assembly of the AAPM&R Botulinum Toxin Workshop. Management of the Patient with Muscle Spasticity and Related Movement Disorders. Marriott’s Orlando World Center. Orlando, Florida. November 20, 1995
6. Botulinum Toxin: Management of Dystonias and Related Disorders. 57th Annual Assembly of the AAPM&R Botulinum Toxin Workshop. Management of the Patient with Muscle Spasticity and Related Movement Disorders. Marriott’s Orlando World Center. Orlando, Florida. November 20, 1995.
7. Case Presentations in Parkinson’s Disease. Kick-off dinner. 48th Meeting of the American Academy of Neurology. San Francisco, California. March 23, 1996.
8. Botulinum Toxin: Management of Dystonia and Spasticity. 20th Annual Meeting of the American Society of Neuroimaging; Interventional Neuroimaging Seminar. San Juan, Peurto Rico. March 8, 1997.
9. Case Studies in Parkinson’s Disease. Kick-off Program. 50th Annual Meeting of the American Academy of Neurology. Minneapolis, Minnesota. March 26, 1998.
30
NATIONAL AND INTERNATIONAL SEMINARS CHAIRED
1. Co-Chair, The Millenium Lectures on Parkinson’s Disease. Miami, Florida. February 19, 2000. Dr. William Koller – Surgical Treatment of Parkinson’s Disease Dr. Theresa Zesiewicz – Case Studies in Parkinson’s Disease Dr. Abraham Lieberman – Use of COMT Inhibitors in Parkinson’s Disease Dr. Robert A. Hauser – Dopamine Agonists in Parkinson’s Disease Dr. William Weiner – Future Therapies in Parkinson’s Disease
2. Chair, The Millennium Lectures on Parkinson’s Disease. Denver, Colorado. June 24, 2000. Dr. Rajesh Pahwa - Differential Diagnosis of Parkinson's Disease Dr. Robert A. Hauser - Levodopa – The Gold Standard in Parkinson's Disease Dr. Jean Hubble – Dopamine Agonists Dr. Robert A. Hauser – The Use of COMT Inhibitors in Parkinson's Disease Dr. Rajesh Pahwa – Surgical Treatment of Parkinson's Disease Dr. Jean Hubble – Video Case Studies – The Management of Parkinson's Disease Dr. Peter LeWitt – Future Therapies for Parkinson's Disease
3. Chair, The Millennium Lectures on Parkinson’s Disease. San Francisco, California. September 9, 2000.
Dr. James Tetrud-Clues to the Etiology of Parkinson's disease Dr. Robert A. Hauser-Levodopa: the Gold Standard in Parkinson's disease Dr. Jean Hubble-Dopamine Agonists Dr. Robert A. Hauser-Use of COMT Inhibitors in Parkinson's disease Dr. Rajesh Pahwa-Surgical Treatment of Parkinson's disease Dr. Jean Hubble-The management of Parkinson's disease Dr. Rajesh Pahwa-Differential Diagnosis of Parkinson's disease Dr. James Tetrud-Future Therapies for Parkinson's disease
4. Chair, The Millennium Lectures on Parkinson's Disease. Chicago, Illinois. October 7, 2000.
Dr. Katie Kompoliti-Clues to the Etiology of Parkinson's disease Dr. Robert A. Hauser-Levodopa-The Gold Standard in Parkinson's disease Dr. Kathleen M. Shannon-Dopamine Agonist Dr. Robert A. Hauser-Use of COMT Inhibitors in Parkinson's disease Dr. Katie Kompoliti-Differential Diagnosis of Parkinson's disease Dr. Kathleen M. Shannon-Surgical Treatment of Parkinson's disease Dr. Un Kang-Future Therapies for Parkinson's disease
31
5. Chair, The Millennium Lectures on Parkinson’s Disease. New York City, New York. December 16, 2000. Dr. Jean Hubble-Clues to the Etiology of Parkinson’s Disease Dr. Robert A. Hauser-Levodopa-The Gold Standard in Parkinsons Disease Dr. Cheryl Waters-Dopamine Agonists Dr. Robert A. Hauser-Use of COMT Inhibitors in Parkinson’s Disease Dr. Theresa Zesiewicz-Differential Diagnosis of Parkinson’s Disease Dr. Richard Penn-Surgical Treatment of Parkinson’s Disease Dr. Jean Hubble- The Management of Parkinson’s Disease Dr. Cheryl Waters-Future Therapies for Parkinson’s Disease 6. Chair, Advances in Managing Diseases of the CNS: Parkinson’s Disease. Charleston,
South Carolina. November 2, 2002. Dr. David Riley – Etiology of Parkinson’s Disease Dr. Robert A. Hauser – Medical Management of Parkinson’s Disease Dr. Ali Rezai – Surgical Treatment of Parkinson’s Disease
7. Co-Chair (with Raj Pahwa), Current Treatment Challenges and Emerging Therapies in Parkinson’s Disease. Dallas, Texas. March 21, 2003.
Dr. James Tetrud – Early Therapy for PD Dr. Warren Olanow – Neuroprotection and disease modification in PD Dr. Raj Pahwa – Motor Fluctuations and dyskinesias Dr. Michel Panisset – Freezing of gait in PD Dr. Robert Hauser – Future Therapies for PD Dr. Lawrence Elmer – Dementia and Cognitive Problems in PD Dr. Jack Chen – Neuropsychiatric Problems in PD Dr. Richard Dewey – Autonomic Dysfunction in PD Dr. Tanya Simuni – Somnolence in PD Dr. Mickie Welsh – Quality of Life in PD
8. Co-Chair (with Niall Quinn), Improving the Recognition of Wearing-off in Parkinson’s
Disease. Seville, Spain. May 7, 2003.
Annette Bowron, MA – Wearing-off: The Patient’s Perspective Dr. Kapil Sethi – Recognizing the Signs and Symptoms of Wearing-off Dr. Fabrizio Stocchi – Linking the Pharmacology of Wearing-off to the symptoms Dr. Mark Stacy – Identifying Wearing-off in Parkinson’s Disease: Comparison of a patient survey versus a programmed investigator evaluation Drs Robert Hauser and Naill Quinn – Interactive panel discussion on wearing-off: from identification to treatment Mary Baker MBE – The Role of the Patient Association
32
OTHER NATIONAL PRESENTATIONS Corticobasal Degeneration presenting as Symmetric Progressive Apraxia without Parkinsonism. Presented at the Unusual Movement Disorders Seminar, 48th Annual Meeting of the American Academy of Neurology. San Francisco, California. March 25,1996. Chediak-Higashi Young Adult Parkinsonian Syndrome. Presented at the Unusual Movement Disorders Seminar, 51st Annual Meeting of the American Academy of Neurology. Toronto, Ontario, Canada. April 19, 1999. Scientific Highlights – Movement Disorders (Neuroimaging), American Academy of Neurology. Platform presentation. 53rd Annual Meeting of the American Academy of Neurology. Philadelphia, Pennsylvania. May 10, 2001. Scientific Highlights – Movement Disorders (Surgery, Sleep Disorders), American Academy of Neurology. Platform Presentation. 54th Annual Meeting of the American Academy of Neurology. Denver Colorado. April 16, 2002. An Algorithm to…Publish An Algorithm. (Humorous Presentation). Platform Presentation. Annual Meeting of the Parkinson Study Group. Coronado, California. May 18, 2002.
33
Invited Speaker - National and International Presentations 1. The Present and Future Management of Parkinson’s Disease. University of Texas Primary Care
Program. Dallas, Texas. December 7, 1991. 2. Mechanisms of Cell Death in Parkinson’s Disease and Implications for Treatment. Grand Rounds,
The Medical Center of Georgia- Mercer University School of Medicine. Macon, Georgia. July 8, 1992.
3. Implications of Oxidation Reactions in Parkinson’s Disease. Grand Rounds. Medical College of
Virginia. Richmond, Virginia. January 28, 1993. 4. Present and Future Treatments for Parkinson’s Disease. Featured Speaker. Inaugural Meeting of the
Movement Disorders Study Groups of Mexico. Zacatecas Mexico. February 23, 1996. 5. Treatment of Parkinson’s Disease in the Long-term setting. 19th Annual Symposium of the American
Medical Directors Association. New Orleans, Louisiana. March 7-8, 1996. 6. Role of Dopamine agonists in the treatment of Parkinson’s disease. Workshop on the role of
selegiline in the treatment of Parkinson’s disease. Dana Point, California. May 4, 1997. 7. Tremor Control Therapy Educational Symposium. Differential diagnosis of the tremor patient; Video
case studies of tremor types and results of deep brain stimulation; Basics of stimulator programming. Chicago, Illinois. May 30-31, 1997.
8. Decision making for the long-term therapeutic management of patients with Parkinson’s disease.
Conference on Current Perspectives on COMT Inhibition and Other Treatment Options for Parkinson’s Disease. Vienna, VA. June 18, 1997.
9. Tremor Control Therapy Educational Symposium. Differential diagnosis of the tremor patient;
Medical management of tremor; Clinical results of multi-center studies of thalamic stimulation - the European and North American safety and efficacy studies; Basics of stimulator programming; Video case studies of tremor types and results of deep brain stimulation. Chicago, Illinois. July 26-27, 1997.
10. New Solutions to Treating Parkinson’s Disease: a focus on long-term care. American Society of
Consultant Pharmacists (ASCP) 1997 Annual Meeting. November 13, 1997. 11. Tremor Control Therapy Educational Symposium. Tremor and its Treatments; Video Workshop -
Case studies of tremor types and results of deep brain stimulation. Chicago, Illinois. December 5, 1997.
12. The Changing Standard of Care in Parkinson’s Disease: the role of dopamine agonists and COMT
inhibitors. Grand Rounds. University of North Carolina College of Medicine. Chapel Hill, North Carolina. January 22, 1998.
13. New Medications and Their Role in the Treatment of Parkinson’s Disease. Memphis, Tennessee.
March 19, 1998.
34
14. Medical and Surgical Treatments for Tremor. Grand Rounds. University of Tennessee. Memphis, Tennessee. March 20, 1998.
15. Botulinum toxin in the treatment of myofascial pain syndrome. New Horizons in Rheumatology.
Indian River Plantation. Stuart, FL. June 12, 1998. 16. Parkinson’s disease and COMT inhibition. Clinical trials in fluctuating patients. Roche speakers
bureau educational symposium. Naples, Florida. June 12-14, 1988. 17. COMT Inhibition for the Treatment of Parkinson’s Disease. XXXVI Congreso Argentino De
Neurologia. Corrientes, Argentina. September 26, 1998. 18. Dopamine Agonists for the Treatment of Parkinson’s Disease. Grand Rounds. Vanderbilt University.
Nashville, Tennessee. September 28, 1998. 19. Medical therapy for Parkinson’s Disease. Grand Rounds. University of Alabama. Birmingham,
Alabama. November 24, 1998. 20. Entacapone for the Treatment of Parkinson's Disease. Consultant’s Meeting. Orlando, Florida. March
25, 2000. 21. Botulinum Toxin for the Treatment of Cervical Dystonia. Ask the Experts Series. 51st Annual
Meeting of the American Academy of Neurology. Toronto, Ontario, Canada. April 21, 1999. 22. Designing and Executing Clinical Trials in Parkinson’s Disease: a daylong seminar. Sponsored by
Quintiles/ARC. Tampa, FL. June 18, 1999. 23. Entacapone for the Treatment of Parkinson’s Disease. Neurology Consultant’s Training Seminar.
Charleston, South Carolina. June 26, 1999. 24. Parkinson’s Disease Consensus Summit. Practical Approahes to the Treatment of Parkinson’s
Disease. San Juan, Peurto Rico. January 26-28, 2001. 25. The Parkinson’s Disease Treatment Paradigm Shift. Grand Rounds. Boston University Medical
Center. Boston, Massachusetts. June 5, 2001. 26. Neuromodulation of Essential Tremor. Grand Rounds. Medical University of South Carolina.
Charleston, South Carolina. August 2, 2001. 27. Evaluation and Treatment of Parkinson’s Disease. Grand Rounds. Ohio State University. Columbus,
Ohio. August 9, 2001. 28. Dopamine Agonists as Early Treatment for Parkinson’s Disease. Grand Rounds. Columbia Veteran’s
Administration Hospital. Columbia, South Carolina. October 14, 2001. 29. Continuous Dopaminergic Stimulation in Early Parkinson’s Disease. Quebec Association of
Neurology. Halifax, Nova Scotia. November 21, 2001. 30. Contemporary Evaluation and Treatment of Parkinson’s Disease. Grand Rounds. Ottawa Hospital.
Ottawa, Ontario. November 23, 2001.
35
31. Medical Management of Early Parkinson’s Disease. 15th Annual Scientific Meeting of the Hong
Kong Neurological Society. Hong Kong. November 18, 2002. 32. Medical Management of Advanced Parkinson’s Disease. 15th Annual Scientific Meeting of the Hong
Kong Neurological Society. Hong Kong. November 18, 2002. 33. Continuous Dopaminergic Stimulation Hypothesis and its Implications for the Treatment of
Parkinson’s Disease. Grand Rounds. University of Wisconsin. November 22, 2002. 34. Triple Combination. Neuroscience Advisory Forum. Seville, Spain. May 5, 2003.
36
INVITED SPEAKER - Other National and International Presentations 1. Use of a home diary to assess functional status in Parkinson’s disease patients with motor
fluctuations and dyskinesia. KW-6002 Investigator’s meeting. Atlanta, Georgia. March 8, 2002. 2. Emerging Developments in PD: A current assessment of COMT inhibition. National Symposium
sponsored Novartis. Miami, Florida. April 5, 2002. 3. Dopamine Agonists and Progression of Parkinson’s Disease. National Symposium sponsored by
Glaxo-SmithKline. New York, New York. April 27, 2002. 4. One Brain, Many Disorders. Diagnosis and Management of Parkinson’s Disease. National
Symposium sponsored by the University of South Florida. Key West, Florida. May 10, 2002. 5. One Brain, Many Disorders. Survey of Movement Disorders. National Symposium sponsored by
the University of South Florida. Key West, Florida. May 10, 2002. 6. Use of a home diary to assess functional status in Parkinson’s disease patients with motor
fluctuations and dyskinesia. Sarizotan Investigator’s meeting. Cancun, Mexico. May 11, 2002. 7. Ropinirole to Slow Progression of Parkinson’s Disease. International Symposium sponsored by
Glaxo-SmithKline. Malta. May 15, 2002. 8. Ropinirole and Restless Legs Syndrome. International Symposium sponsored by Glaxo-
SmithKline. Malta. May 16, 2002. 9. Use of a home diary to assess functional status in Parkinson’s disease patients with motor
fluctuations and dyskinesia. Sarizotan Investigator’s meeting. Bandol, France. May 27, 2002. 10. Emerging Treatment Strategies in Parkinson’s Disease. National Symposium sponsored Novartis.
Los Angeles, California. June 1, 2002. 11. Update on COMT inhibition. National Symposium sponsored Novartis. Chicago, Illinois. June
15, 2002. 12. Use of the “Hauser” home diary in PD clinical trials. Sarizotan Investigator’s meeting. Rome,
Italy. September 5, 2002. 13. Use of the “Hauser” home diary in PD clinical trials. Spheramine Investigator’s meeting. New
York, NY. October 15, 2002. 14. Treatment of Early Parkinson’s Disease. The Keys to Neurology Series: Diagnosis and
Management of Abnormal Movements. National Symposium sponsored by Glaxo-SmithKline. Miami, Florida. October 19, 2002.
15. Use of the “Hauser” home diary for clinical trials in advanced PD. NS233 Investigator’s meeting.
Versailles, France. February 26, 2003.
37
16. Levodopa/carbidopa/entacapone triple combination. New York, NY. February 28, 2003. 17. The Role of Levodopa/carbidopa/entacapone Combination Treatment for Parkinson’s Disease.
Optimizing Levodopa Therapy. International Symposium sponsored by Novartis and Orion Pharma Neuroscience. Seville, Spain. May 6, 2003.
38
INVITED SPEAKER - Regional Presentations 1. Therapy of Parkinson’s Disease. Movement Disorders: Advances and Current Treatment. Annual Conference on Epilepsy, Orlando, Florida, June 8, 1989 2. Transplantation in Parkinson’s Disease. Movement Disorders: Advances and Current Treatment. Annual Conference on Epilepsy, Orlando, Florida, June 8, 1989 3. Update on Evaluation and Treatment of Parkinson’s Disease. Endocrine and Neurological Disorders: Implications for the Practice of Psychiatry. University of South Florida, Tampa, Florida, November 8, 1989 4. Update on Parkinson’s Disease and Other Movement Disorders. A Saturday Morning in Psychiatry. Tampa, Florida. March 24, 1990. 5. Oxidation Reactions and the Management of Parkinson’s Disease. 12th Annual Family Practice Review. St. Petersburg, Florida. April 2, 1990. 6. Parkinson’s Disease: New Frontiers. The Orlando Family Medicine Review Course. Orlando, Florida. July 3, 1990. 7. The Current Management of Parkinson’s Disease. Pinellas Pharmacists Society, St. Petersburg, Florida, September 18, 1990. 8. Overview of Parkinson’s Disease. Fitzgerald, Georgia, December 11, 1990. 9. The Role of Eldepryl in the Management of Parkinson’s Disease. Medical Grand Rounds. Phoebe Putney Hospital. Albany, Georgia, December 12, 1990. 10. Treatment Strategies for Parkinson’s Disease. Grand Rounds. Bay Medical Center, Panama City, Florida. January 15, 1991. 11. Parkinson’s Disease: Clinical Assessment and Management. Tallahassee Physician’s Assistants Society, Tallahassee, Florida. January 15, 1991. 12. New Directions in the Treatment of Parkinson’s Disease. Tampa Bay Pharmacist’s association. Memorial Hospital, Tampa, Florida. January 17, 1991. 13. Emerging Treatment Strategies for Parkinson’s Disease. Florida Hospitals-Grand Rounds. Orlando, Florida. February 12, 1991. 14. Parkinson’s Disease: Shortcomings of Current Management and New Directions for the Future. Cutsbert, Georgia. April 16, 1991. 15. Does Selegiline Really Slow the Progression of Parkinson’s Disease? A Critical Appraisal.
Jensen Beach, Florida. May 2, 1991.
39
16. 16. Neuroprotective Strategies in Parkinson’s Disease. Grand Rounds, Sumter Hospital, Americus,
Georgia. May 9, 1991. 17. What’s Wrong with Current Therapy for Parkinson’s Disease ? Titusville, Florida. June 18, 1991. 18. Where Do We Go from Here in the Treatment of Parkinson’s Disease? Salisbury, North Carolina. July 23, 1991. 19. Making the Most of Current Therapies for Parkinson’s Disease. Grand Rounds, Piedmont
Medical Center, Rock Hill, South Carolina. July 24, 1991. 20. Primary Care of Parkinson’s Disease. Macon, Georgia. August 15, 1991. 21. Parkinson’s Disease: Does Early Therapy Affect Outcome? Sebastion Summer Conference, Melbourne, Florida. August 23, 1991. 22. Shortcomings of Parkinson’s Disease Management. Grand Rounds, Indian River Memorial Hospital, Vero Beach, Florida. September 24, 1991. 23. Parkinson’s Disease Seminar. Oxford, Mississippi, October 12, 1991. 24. The Future of Parkinson’s Disease Management. Boynton Beach, Florida. October 30, 1991. 25. Making the Most of Current Medications for Parkinson’s Disease. Grand Rounds, Highlands Regional Medical Center, Sebring, Florida. December 5, 1991. 26. Attempting to Understand Parkinson’s Disease and its Treatment. Moultrie, Georgia. January 14, 1992. 27. Optimizing Anti-Parkinsonian Therapy. Melbourne, Florida. January 23, 1992. 28. Management Issues in Parkinson’s Disease. West Palm Beach, Florida. January 30, 1992. 29. Research Directions in Parkinson’s Disease. Grand Rounds, West Volusia Hospital. Deland, Florida. February 6, 1992. 30. Basic Management of Parkinson’s Disease. Florida State Physicians Assistants Annual Medical Conference. Jacksonville, Florida. February 23, 1992. 31. Toward Better Management of Parkinson’s Disease. Grand Rounds, Martin Memorial Hospital. Stuart, Florida. March 10, 1992. 32. Etiology, Diagnosis and Management of Parkinson’s Disease. Waycross, Georgia. April 2, 1992. 33. Current Therapy for Parkinson’s Disease. Eleventh Annual Continuing Medical Education Program- Association of Philippine Physicians. Roanoke, VA. April 4, 1992. 34. Update on Therapies for Parkinson’s Disease. Tifton, Georgia. April 9, 1992.
40
35. Neuroprotective Therapy for Parkinson’s Disease. Grand Rounds, South Bay Hospital. Sun City Center, Florida. April 13, 1992. 36. Pharmacotherapy for Parkinson’s Disease. Florida Pharmacists Association. Halifax Hospital. Daytona Beach, Florida. May 20, 1992. 37. Slowing Progression of Parkinson’s Disease? Orlando, Florida. June 3, 1992. 38. Research Frontiers in Parkinson’s Disease. Neurodegenerative Conference Series. Holmes Regional Medical Center/ Florida Institute of Technology. June 8, 1992. 39. Inadequacies of Long-term Parkinson’s Disease Management. Implications for future Therapy. Grand Rounds, Lawnwood regional Medical Center. Fort Pierce, Florida. June 12, 1992. 40. Delaying Disability in Parkinson’s Disease. Phillippine-American Medical Conference. Jacksonville, Florida. June 19, 1992. 41. Current Strategies for Treating Parkinson’s Disease. Orlando, Florida. June 24, 1992. 42. Levodopa Pharmacokinetics- Implications for Treating Parkinson’s Disease. Tallahassee, Florida.
June 25, 1992. 43. Symptomatic and Neuroprotective Therapy for Parkinson’s Disease. Greenville, SC. August 12, 1992. 44. Research Directions in Parkinson’s Disease. Greenville, SC. August 13, 1992. 45. Medical and Surgical therapies for Parkinson’s Disease. Grand Rounds, Holmes Regional
Medical Center. Melbourne, Florida. August 21, 1992. 46. Update on Parkinson’s Disease for the Nineties and Beyond. Saddlebrook, Florida. August 22, 1992. 47. Rational Strategies for Treating Parkinson’s Disease. Florida Osteopathic Medical
Society.Daytona Beach, Florida. August 27, 1992. 48. Neuroprotection, Trophic Factors, and Other Future Therapies for Parkinson’s Disease. Boca Raton, Florida. September 3, 1992. 49. Improving Therapy for Parkinson’s Disease. Brookesville, Florida. September 17, 1992. 50. 50. Advanced Treatment Strategies for Parkinson’s Disease. Johnson City, Tennessee.
September 24,1992. 51. Understanding Parkinson’s Disease Therapy. Grand Rounds, HCA Raulerson Hospital.
Okeechobee, Florida. September, 30, 1992. 52. Introduction to Medical Management to Parkinson’s Disease. Grand Rounds, Suncoast Hospital.
Largo, Florida. October 1, 1992.
41
53. Standard and Emerging Therapies for Parkinson’s Disease. Grand Rounds, The Medical Center of Central Georgia, Crisp County Hospital. Waycross, Georgia October 29, 1992.
54. Emerging Strategies for the Treatment of Parkinson’s Disease. Grand Rounds, Southeast Georgia
Regional Medical Center. October 20, 1992. 55. Movement Disorders: Identification, Diagnosis and Treatment. Eleventh Annual Continuing
Medical Education Program, Crafts-Farrow State Hospital. Columbia S.C. November 5, 1992. 56. Diagnosis and Treatment of Parkinson’s Disease. Parkinson’s Disease and Dystonia; and Update.
Tampa, Florida. November 19, 1992. 57. New Developments in the Treatment of Parkinson’s Disease. Fort Myers, Florida. November 10,
1992. 58. Oxidation and the Progression of Parkinson’s Disease. Deland, Florida. December 2, 1992. 59. Advances in the Pathogenesis, Etiology and Treatment of Stroke. Islamic Medical Association
Annual Meeting. Tampa, Florida. January 23, 1993. 60. Maximizing Long-term Therapy for Parkinson’s Disease. Grand Rounds, Humana Hospital.
Crestview, Florida. January 26, 1993. 61. Deprenyl as Neuroprotective Therapy. Orlando, Florida. February 11, 1993. 62. Neuroprotective Therapy for Parkinson’s Disease - Implications of the DATATOP Study. Grand
Rounds, Roper Hospital. Charleston, South Carolina. February 16, 1993. 63. Neuroprotective Therapy for Parkinson’s Disease - Implications of the DATATOP Study. 64. Directors of Nursing Annual Meeting. Capital Healthcare. Tallahassee, Florida. February 17,
1993. 65. Understanding and Interpreting the DATATOP Study. Grand Rounds, Holmes Regional
Medical Center. Melbourne, Florida. February 19, 1993. 66. Eldepryl and the DATATOP Study: Implications for Neuroprotective Therapy for Parkinson’s
Disease. Stuart, Florida. February 26, 1993. 67. The DATATOP Study: Neuroprotective versus Symptomatic Effects. Jacksonville, Florida.
March 4, 1993. 68. DATATOP and Parkinson’s Disease Management. Grand Rounds, Bay Medical Center. 69. Panama City, Florida. March 9, 1993. 69. Update on the Management of Parkinson’s Disease. Ocala, Florida. March 11, 1993. 70. The Meaning of DATATOP. Lake Wales, Florida. March 12, 1993. 71. Advances in Diagnosis and Management of Parkinson’s Disease. 37th Annual Greenville Post
42
Graduate Medical Seminar. Greenville, South Carolina. March 24, 1993. 72. Medical and Surgical Therapy for Parkinson’s Disease. Grand Rounds, HCA Hospital. New Port
Richey, Florida. March 22, 1993. 73. Current Status of Neuroprotective Therapy for Parkinson’s Disease. Jacksonville, Florida. May
20, 1993. 74. Rethinking Parkinson’s Disease Management. Grand Rounds, University of Florida. Gainesville,
Florida. June 8, 1993.
75. Emerging Medical and Surgical Therapies for Parkinson’s Disease. Grand Rounds, Halifax Medical Center. Daytona Beach, Florida. July 22, 1993.
76. Current and Future Therapies for Parkinson’s Disease. Clearwater, Florida. August 5, 1993. 77. Unusual Movement Disorders Video Seminar. Clearwater, Florida. September 2, 1993. 78. Uncommon Problems and Management Strategies in Parkinson’s Disease. West Palm Beach,
Florida. September 13, 1993.
79. New Concepts in Stroke Diagnosis and Therapy. Annual Meeting of the Philippine Medical Association. Orlando, Florida. October 22, 1993.
80. Movement Disorders: Recognition, Diagnosis and Treatment. Florida Academy of Family Physician 64th Family Practice Weekend. Daytona Beach, Florida. November 19, 1993.
81. Stroke Prevention. Orlando Health Center. Grand Rounds. Orlando, Florida. September 15,1994. 82. Maximizing Stroke Therapy. Orlando, Florida. October 27, 1994. 83. Medical and Surgical Advances in the Treatment of Parkinson’s Disease. Watson Clinic 39th
Annual Spring Seminar. Lakeland, Florida. March 11, 1995.
84. Mechanisms of Neuroprotection. Tarpon Springs, Florida. May 27, 1995. 85. Taking Control of Parkinson’s Disease. A National Symposium for Patients, Caregivers and
Physicians. June 14, 1995. Local moderator, Hyatt Regency Tampa, Tampa, Florida.
86. 86. Research Issue in Parkinson’s Disease. University of South Florida Biomedical Aging Program.
Tampa, Florida. November 9, 1995.
87. Developments in new medications for Parkinson’s disease: dopamine agonists and COMT inhibitors. Tampa FL. December 14, 1997.
88. New medications for Parkinson’s disease: dopamine agonists and COMT inhibitors. Birmingham
Alabama. April 3, 1997. 89. Therapy and Management of Parkinson’s Disease. Fort Myers, FL. April 25, 1997.
43
90. New dopamine agonists and COMT inhibitors for the treatment of Parkinson’s disease. Sarasota,
Florida. June 12, 1997. 91. New medications for the treatment of Parkinson’s disease. Winston-Salem, North Carolina. June
18, 1997. 92. New medications for the treatment of Parkinson’s disease. Greensboro, North Carolina. June 19,
1997. 93. Thalamic Stimulation for Parkinson’s disease: what it can and cannot do. Saint Petersburg,
Florida. June 21, 1997. 94. New dopamine agonists and COMT inhibitors for the treatment of Parkinson’s disease. Orlando,
FL. July 22, 1997. 95. Dopamine agonists in the elderly Parkinson’s disease patient. Tallahassee, FL. October 30, 1997.
The changing standard of care in Parkinson’s disease. Ft. Lauderdale, FL. November 6, 1997.
96. New Dopamine agonists and COMT inhibitors. The role of new medications in the treatment of Parkinson’s disease. Grand Rounds, Holmes Regional Medical Center. Melbourne, FL. December 19, 1997.
97. Treatment controversies in the management of Parkinson’s disease. Orlando, FL. January 16,
1998. 98. New treatments for Parkinson’s disease. Ninth annual osteopathic winter seminar. St. Pete Beach.
January 30, 1998. 99. The role of COMT inhibitors in the treatment of Parkinson’s disease. Atlanta, Georgia. April 4,1998. 100. New advances in the treatment of Parkinson’s disease. Grand Rounds. Florida Hospital. Orlando,
Florida. April 9, 1998. 101. Current treatment advances in Parkinson’s disease. Daytona Beach, FL. May 7, 1998. 102. COMT inhibition for the treatment of Parkinson’s disease. Naples, FL. June 9, 1998. 103. Dopamine agonists and COMT inhibitors in the treatment of Parkinson’s disease. Grand Rounds.
Bayonet Point Hospital. July 16,1998. 104. Long-term considerations in the treatment of Parkinson’s disease. Savannah, GA. July 23, 1998. 105. COMT inhibition for the treatment of Parkinson’s disease. Clearwater, FL. September 22, 1998. 106. New therapies for the treatment of Parkinson’s disease. Grand Rounds. Bradenton, FL. October 1,
1998.
44
107. Thalamic stimulation for the treatment of Parkinson’s and essential tremor. Tampa, FL. October 1, 1998.
108. Current therapies for Parkinson’s disease. Jacksonville, FL. October 5, 1998. 109. Parkinson’s disease: etiology, phenomenology, and treatment. Baptist Medical Center. Grand
Rounds. Jacksonville, FL. October 6, 1998. 110. Old and new dopamine agonists. Orlando, FL. October 16, 1998. 111. New therapies for Parkinson’s disease. Coral Springs, FL. October 20, 1998. 112. COMT inhibition for the treatment of Parkinson’s disease. Bradenton, FL. October 26, 1998. 113. New therapies for Parkinson’s disease. Lakeland, FL. October 27, 1998. 114. Medical therapy for Parkinson’s disease. Ocala, FL. November 18, 1998. 115. The role of COMT inhibition in the treatment of Parkinson’s disease. Springhill, FL. December 1,
1998. 116. New dopamine agonists for Parkinson’s disease. Tampa, FL. December 2, 1998. 117. Sinemet CR versus immediate release in the treatment of Parkinson’s disease. Tampa, FL.
December 14, 1998. 118. Botulinum toxin full day conference: Pharmacology, Preparation, and Side Effects; Management
of Dystonias and Related Disorders; Management of Spasticity; Injection Workshop. Bays Medical Society. Panama City, Florida. March 24,1999.
119. Tolcapone and Hepatotoxicity. New Port Richey, Florida. April 27, 1999. 120. The Future Direction of Parkinson’s Disease Research. Innisbrook, Florida. June 12, 1999. 121. Dopamine Agonists in the Treatment of Parkinson’s disease: efficacy, usefulness, and side
effects. NPF Annual Centers of Excellence Patient Coordinator Conference. Miami, Florida. August 28,1999.
122. New Medications for Parkinson’s Disease. Port Charlotte, Florida. September 11, 1999. 123. Dopamine Agonists: Dyskinesia and Somnolence. Naples, Florida. October 29, 1999. 124. Improving Levodopa Pharmacokinetics. Tampa, Florida. December 1, 1999. 125. Dopamine Agonists: Efficacy, Usefulness, and Side Effects. Saint Louis, Missouri. December 9,
1999. 126. Treatment of Parkinson’s Disease. USF Symposium. Long Boat Key, Florida. January 15, 2000.
45
127. Initial Treatment of Parkinson’s Disease with Ropinirole Reduces Long-term Dyskinesia. Tampa, Florida. January 20, 2000.
128. Diagnosis, Etiology, and Treatment of Parkinson’s Diease. Grand Rounds, Bay Pines VA
Medical Center. Saint Petersberg, Florida. February 23, 2000. 129. Treatment Issues in Parkinson’s Disease. Marco Island, Florida. June 2-4, 2000. 130. Advances in Neurology and Parkinson's Disease. Naples, FL. July 15-16, 2000. 131. Parkinson’s Disease. Neurology for the Non-Neurologist. The Bays Medical Society. Panama
City, Florida. October 21, 2000. 132. New Dopamine Agonists in Parkinson’s Disease. Fort Lauderdale, Florida. November 1, 2000. 133. Advances in the Treatment of Parkinson’s Disease. Neurology Clinical Forum. Palm Beach,
Florida. November 10-12, 2000. 134. Paradigm Shift: The role of Dopamine Agonists in Early and Late Parkinson’s Disease. Kansas
City, Missouri. December 6, 2000. 135. Early Use of Dopamine Agonists in the Treatment of Parkinson’s Disease. Tampa, Florida,
January 20, 2000. 136. Paradigm Shift: The role of Dopamine Agonists in Early and Late Parkinson’s Disease. Des
Moines, Iowa. March 17, 2001. 137. COMT inhibition and Continuous Dopaminergic Stimulation. Jacksonville, Florida. March 21,
2001. 138. Ropinirole causes less dyskinesia than levodopa: 5-yr data. Oklahoma City, Oklahoma. April 19,
2001. 139. Scientific Rationale for Continuous Dopaminergic Stimulation. West Palm Beach, Florida. April
24, 2001. 140. Dopamine Agonists Cause Less Dyskinesia than Levodopa. May 2, 2001. Grand Rounds. Saint
Petersburg General Hospital. Saint Petersburg, Florida.
141. Parkinson’s Disease evaluation and management. Geriatric Medicine for the Primary Care Physician Summer Conference. Orlando, FL. July 6, 2001.
142. COMT therapy in the management of Parkinson’s Disease. Columbus, Ohio. August 8, 2001. 143. Advances in Botulinum Toxin Treatment for Cervical Dystonia. Saint Petersburg, Florida.
August 30, 2001. 144. Dopamine Agonists as Early Treatment for Parkinson’s Disease. Naples, Florida. October 16,
2001.
46
145. Evaluation and Treatment of Parkinson’s Disease. Grand Rounds. Naples Community Hospital. Naples, Florida. October 17, 2001.
146. Scientific Rationale for Continuous Dopaminergic Stimulation. Tampa, Florida. November 28,
2001. 147. Practicum in Neurology: Management decisions in the treatment of early Parkinson’s disease –
levodopa versus dopamine agonists. Key Largo, Florida. February 9, 2002. 148. Update on Medical Management of Parkinson’s Disease. Naples, Florida. March 18, 2002. 149. Continuous dopaminergic stimulation and long-term motor complications in Parkinson’s Disease.
Mirapex Regional Advisory Board. Palm Beach, Florida. March 23, 2002. 150. Dopamine Agonists and Progression of Parkinson’s Disease. Sarasota, Florida. May 1, 2002. 151. Dopamine Agonists and Progression of Parkinson’s Disease. Melbourne, Florida. May 23, 2002. 152. Emerging Treatment Strategies in Parkinson’s Disease. Maitland, Florida. June 11, 2002. 153. Emerging Role of Dopamine Agonists in the Treatment of Parkinson’s Disease. Boca Raton,
Florida. June 13, 2002. 154. COMT inhibitors and the Continuous Dopaminergic Stimulation hypothesis. Fort Myers, FL. July
12, 2002. 155. COMT inhibitors and the Continuous Dopaminergic Stimulation hypothesis. West Palm Beach,
FL. July 13, 2002. 156. Scientific Rationale for the Continuous Dopaminergic Stimulation hypothesis in PD. Sarasota,
FL. August 1, 2002. 157. Update on medical management of Parkinson’s disease. Fort Myers, FL. October 17, 2002. 158. Optimizing the approach to early treatment of Parkinson’s disease. Advances in Managing Diseases of the CNS. Charleston, SC. November 2, 2002. 159. Medical Management of Parkinson’s Disease. Grand Rounds. St. Mary’s Hospital. Madison, Wisconsin. November 21, 2002. 160. Medical Management of Parkinson’s Disease. An Update on Movement Disorders. Seminar sponsored by the University of Kansas. Kansas City, Missouri. December 14, 2002. OTHER NATIONAL TEACHING ACTIVITIES
Professor’s Rounds. Case Studies with residents. University of Wisconsin. Madison, Wisconsin. November 22, 2002.
47
MODERATOR Surgical therapies workshop. Parkinson Study Group. February 28, 1998.
Co-Chair, Neurology Science Committee and Scientific Program Subcommittee Session S64, American Academy of Neurology 52nd Annual Meeting, May 4, 2000.
NATIONAL COMMUNITY LECTURES
1. Research update on fetal transplantation for Huntington’s disease. Twelfth annual Huntington’s Disease Society of America convention. Rochester, New York. June 27, 1997.
2. Fetal Cell Transplantation in Huntington’s Disease. Annual Convention of the Huntington’s Disease
Society of America. Orlando, Florida. June 9-11, 2000. REGIONAL COMMUNITY LECTURES 1. The Physician’s Perspective on Parkinson’s Disease. Longboat Key Parkinson’s Disease Support
Group. Longboat Key, Florida. January 25, 1991. 2. Parkinson’s Disease - An Overview for Patients. Sarasota Parkinson’s disease Support Group.
Sarasota, Florida. February 11, 1991. 3. What Your Physician Should Know About Parkinson’s Disease. Sun City Parkinson’s Disease
Support Group. Sun City Center, Florida. February 19, 1991. 4. What is Stroke? Positive Outcomes from Negative. Strokes Workshop, Tampa General Hospital
Rehabilitation Center. Tampa, Florida. February 21, 1991. 5. What’s New in the Treatment of Parkinson’s disease? West Pasco Parkinson’s Disease Support
Group. Hudson, Florida. April 4, 1991.
6. Multiple Sclerosis- An Overview for Patients. Gulf Coast MS Chapter. Sheraton Grand Hotel, Tampa, Florida. May 18, 1991.
7. New Therapies for Parkinson’s Disease. Suncoast Parkinsonians Support Group. St. Petersburg,
Florida. September 9, 1991. 8. How Anti-parkinsonian Medications Should Be Used. Hillsborough County Parkinson’s Disease
Support Group. Florida Mental Health Institute, Tampa, Florida. October 17, 1991. 9. Effective Management of Parkinson’s Disease. West Pasco Parkinson’s Disease Support Group.
New Port Richey. January 2, 1992. 10. What is MS and How is it Treated? Florida Gulf Coast Chapter of the National Multiple Sclerosis
Society. Newly Diagnosed Seminar. Tampa, Florida. January 8, 1992.
48
11. Etiology, Diagnosis and Treatment of Parkinson’s Disease. Lakeland Parkinson’s Disease Support
group. Lakeland, Florida. February 12, 1992. 12. Understanding Multiple Sclerosis and Its Management. Newly Diagnosed MS Support Group.
Saint Joseph’s Hospital. Tampa, Florida. May 28, 1992. 13. Advanced Treatment Strategies for Parkinson’s Disease. Manasota Parkinson’s Disease Support
Group. Bradenton, Florida. November 9, 1992. 14. New Developments in the Treatment of Parkinson’s Disease. Winter Park Civic Center. Winter
Haven, Florida. November 13, 1992. 15. Medical and Surgical Treatment of Parkinson’s Disease. WSUN Radio. Tampa Bay, Florida.
February 10, 1993. 16. Eldepryl and the DATATOP Study - What it Means for Patients with Parkinson’s Disease. Fort
Myers Parkinson’s Disease Support Group. Fort Myers, Florida. February 25, 1993. 17. Eldepryl and the DATATOP Study - What it Means for Patients with Parkinson’s Disease. North
Port Parkinson’s Disease Support Group. Port Charlotte, Florida. February 25, 1993. 18. Advances in Diagnosis and Treatment of Parkinson’s Disease. St. Petersburg Parkinson’s Disease
Support Group. St. Petersburg, Florida. April 12, 1993. 19. Movement Disorders: A Video Seminar. Tampa General Hospital. Tampa, Florida. November 4,
1993. 20. New Medical and Surgical Therapies for Parkinson’s Disease. Seventh Annual Parkinson’ s
Disease Patient and Family Seminar. Holy Cross Hospital. Fort Lauderdale, Florida. November 13, 1993.
21. Botulinum Toxins for the Treatment of Dystonias. Tampa Bay National Spasmodic Torticollis
Association Support Group Inaugural Meeting. Tampa, Florida. February 4, 1995.
22. New Forms of Therapy for Parkinson’s Disease. West Coast Florida Parkinson’s Disease Support Group. University of South Florida, Tampa, Florida March 16, 1995.
23. Status of Clinical Trials for Huntington’s Disease. Florida West Coast Huntington’s Disease Support
Group. Tampa, Florida. September 17, 1995. 24. Surgical Treatments for Parkinson’s Disease. Lee Memorial Health System. Parkinson’s Seminar for
Support Group. Ft. Myers, Florida. Novemeber 16, 1995. 25. Update on Deprenyl. Suncoast Parkinson’s Support Group. St. Petersburg, FL February 12, 1996. 26. New Dopamine Agonists and COMT inhibitors. TGH senior health series. Sun City Center, Fl
November 13, 1996.
49
27. New Medications for Parkinson’s disease. Ocala Parkinson’s support group. Ocala, FL November 21, 1996.
28. New Dopamine agonists and COMT inhibitors for Parkinson’s Disease. Ruth Eckerd Hall,
Clearwater, FL. January 9, 1997. 29. Essential Tremor: current treatments and surgical options. Hauser R, Hallet M. Hosted by the
International Tremor Foundation. MacInnes Auditorium, Tampa, FL. January 11, 1997. 30. New Medications for Parkinson’s disease. Lake County Parkinson’s Support Group. Leesburg, FL.
January 14, 1997. 31. New Therapies for Spasticity: Medications, Botulinum Toxin, and Intrathecal Baclofen. National
Multiple Sclerosis Society, Florida Gulf Coast Chapter. Tampa, FL. April 22, 1997. 32. New Medications and Strategies for the Treatment of Parkinson’s disease. Leesburg Parkinson’s
Support Group. Leesburg, FL. January 13, 1998. 33. Parkinson’s Disease: Meeting the Challenge. National Parkinson Foundation. Clearwater, Florida.
January 29,1998. 34. Parkinson’s Disease: Meeting the Challenge. Orlando, Florida. February 24, 1998. 35. Medical Therapy for Parkinson’s Disease. Tampa General Hospital Sun City Seniors Health Series.
March 4, 1998. 36. Parkinson’s Disease. Aging Successfully Lecture Series. Ruth Eckard Hall. Clearwater, Florida.
March 3, 1998. 37. COMT inhibitors: new medications for the treatment of Parkinson’s disease. Bradenton Parkinson’s
disease support group. Bradenton, Florida. June 15, 1998. 38. USF mini-med school: Parkinson’s Disease. Sun City Center. March 2, 1999. 39. Medical and Surgical Treatment of Parkinson’s disease. American Parkinson’s Disease Association
support group. Clearwater, Florida. October 14, 1999. 40. Medical and Surgical Treatment of Parkinson’s disease. American Parkinson’s Disease Association
support group. Lakeland, Florida. November 10, 1999. 41. Dopamine Agonists: Dyskinesia and Somnolence. West Pasco PD support group. Port Richey,
Florida. January 6, 2000. 42. Current Research in Huntington’s Disease. Huntington’s Disease Support Group. Tampa, Florida.
January 6, 2000. 43. New Medications for Parkinson’s Disease. Sarasota, Florida. January 8, 2000. 44. Towards Neuroprotection for Parkinson’s Disease. Leesburg, Florida. February 8, 2000.
50
45. Current and Future Treatments for Parkinson’s Disease. Orlando, Florida. February 12, 2000. 46. Diagnosis Parkinson’s Disease: What happens now? Young Parkinson’s Symposium. Saint
Petersburg, Florida. February 24, 2001. 47. New Management Strategies in Parkinson’s Disease. Springhill Support Group. Springhill, Florida.
September 4, 2001. 48. Diagnosis and Management of Parkinson’s Disease. East Pasco Support Group. January 16, 2002 49. New Developments in the Treatment of Parkinson’s Disease. Inverness Support Group. February 5,
2002 50. New Developments in the Treatment of Parkinson’s Disease. Lake County Parkinson’s Support
Group. February 9, 2002. 51. Night School for the Brain. Parkinson’s Disease: From Diagnosis to Surgical Therapies to Cell
Transplantation. Diagnosis and Medical Management of Parkinson’s Disease. Tampa General Healthcare. February 20, 2002.
52. Update on Diagnosis and Treatment of Parkinson’s Disease. Daytona Beach, Florida. February 6,
2003. 53. Changing Treatment Strategies in Parkinson’s Disease. Brooksville, Florida. March 4, 2003.
51
Regional Courses and Seminars Directed Hauser RA. Course Director: Neurology in the New Millenium 2003. Lecture: Medical Management of Parkinson’s Disease. April 13, 2002. Tampa FL. Hauser RA. Update on the medical management of Parkinson’s disease. Third Annual Advances in Managing Diseases of the Central Nervous System: Multiple Sclerosis and Parkinson’s Disease. USF COM Activity. November 2-3, 2002. Charleston, South Carolina. Hauser RA. Course Director: Neurology in the New Millenium 2003. Lecture: Medical Management of Parkinson’s Disease. April 26, 2003. Tampa FL. Hauser RA. Update on the medical management of Parkinson’s disease. Third Annual Advances in Managing Diseases of the Central Nervous System: Multiple Sclerosis and Parkinson’s Disease. USF COM Activity. November 8-9, 2003. Ashville, North Carolina. Hauser RA. Course Director: Neurology in the New Millenium 2004. Lecture: Medical Management of Parkinson’s Disease. October 30, 2004. Tampa FL. Hauser RA. Update on the medical management of Parkinson’s disease. Third Annual Advances in Managing Diseases of the Central Nervous System: Multiple Sclerosis and Parkinson’s Disease. USF COM Activity. November 13-14, 2004. White Sulfur Springs, West Virginia.
Director, Parkinson’s Disease Seminar for Patients and Caregivers. In association with Tampa General Hospital and the University of South Florida. Tampa General Hospital. Tampa, Florida. December 3, 1994.
Dr. Theresa Zesiewicz - Overview of Parkinson’s Disease Dr. Robert Hauser - Advances in Medical Therapy for Parkinson’s Disease Dr. Thomas Freeman - Fetal Transplantation for Parkinson’s Disease Dr. Donald Smith - Thalamic Stimulation for Tremor
282 in attendance
Director, Spasticity Seminar for Patients and Caregivers. In association with Tampa General Healthcare and the University of South Florida. Tampa General Hospital. Tampa, Florida.
December 7, 1996.
Dr. Susan Alden - Pathophysiology of Spasticity Dr. Robert Hauser - Management of Spasticity with Botulinum Toxin injections Pam Martin, RN - Management of Spasticity with Intrathecal Baclofen Kathleen Albany, PT, MPH - Physical Therapy Interventions for Spasticity
52
Director, Parkinson’s Disease Seminar for Patients and Caregivers. In association with Tampa
General Healthcare and the University of South Florida. College of Public Health. Tampa, Florida. March 14, 1998.
Dr. Juan Sanchez-Ramos - Clues to the Etiology of Parkinson’s Disease Dr. Robert Hauser - Medical Management of Parkinson’s Disease Dr. Theresa Zesiewicz - Treatment of Secondary Symptoms of Parkinson’s Disease Dr. Fernando Valle - Pallidotomy for Parkinson’s Disease Dr. Donald Smith - Stimulation Surgeries for Parkinson’s Disease Dr. Thomas Freeman - Cell Transplantation Strategies for Parkinson’s Disease
400 in attendance
Director, Parkinson’s Disease Seminar for Patients and Caregivers. In association with Tampa
General Healthcare and the University of South Florida. College of Public Health. Tampa, Florida. March 23, 1999.
Dr. Theresa Zesiewicz – Overview of Parkinson’s Disease Dr. Juan Sanchez-Ramos - Clues to the Etiology of Parkinson’s Disease Dr. Robert Hauser - Medical Management of Parkinson’s Disease Dr. Fernando Valle - Pallidotomy for Parkinson’s Disease Dr. Donald Smith - Stimulation Surgeries for Parkinson’s Disease Dr. Thomas Freeman - Cell Transplantation Strategies for Parkinson’s Disease 350 in attendance
Director, Neurology in the New Millennium 2003. Tampa, Florida. April 26, 2003. Dr. William Tatum – Pharmacotherapy for Epilepsy Dr. Selim Benbadis – When Drugs Fail to Control Seizures: Non-pharmacologic Options Dr. Robert Hauser - Management of Parkinson’s Disease 2003. Dr. Maria-Carmen Wilson – Management of the Intractable Headache Patient Dr. Peter Dunne – Multiple Sclerosis: Symptoms and Primary Disease Management Dr. Carolyn Geis – Evaluation and Management of Spasticity: Focus on BotulinumToxin
Dr. Michael Hoffman – Advances in Stroke and Cerebrovascular Disease
Director, Neurology in the New Millennium 2004, Tampa, Florida. October 30, 2004 Dr. William Tatum – Epilepsy: Matching the Medicine to the Patient Dr. Selim Benbadis – Approach to Medically Refractory Seizures: “When Drugs Fail” Dr. Amanda G. Smith – Diagnosis and Management of Dementia Dr. Carolyn Geis – Treatment of Post-Stroke Spasticity with Botulinum Toxin Dr. Robert Hauser – Medical Management of Parkinson’s Disease: 2004 Dr. Fernando Vale – Surgery for Parkinson’s Disease Dr. B. Ashok Raj – Treatment of Depression Dr. Peter Dunne – Multiple Sclerosis – Advances in Disease and Symptom Treatment Dr. Michael W. Hoffman – The Multifaceted Advances in Cerebral Vascular Disease Dr. Charles W. Brock – Neuropathic Pain
53
SELECTED INTRAMURAL PRESENTATIONS 1. Introduction to Laboratory Tests in Neurology. Department of Neurology New Resident Orientation.
July 1, 1999. 2. Parkinson’s Disease Supertalk: Etiology, epidemiology, and treatment. (2 hrs). Department of
Neurology Grand Rounds. September 23, 1999. 3. Lessons from DATATOP. Neurology Resident Journal Club. October 28, 1999. 4. Parkinson’s Disease: The big picture. Neurology Interest Group. 1st-4th Year Medical Students. (2
hrs.) November 1, 1999. 5. Dopamine Agonists versus Levodopa in the Treatment of Parkinson’s Disease: Dyskinesias and
Somnolence. Department of Pharmacology Grand Rounds. November 9, 1999. 6. Parkinson’s Disease in an Aging Population. Biomedical Aging Course. November 30, 1999. 7. Phenomenology and Treatment of Tremor. Department of Neurology Grand Rounds. December 2,
1999. 8. COMT Inhibitors in the Treatment of Parkinson’s Disease. Department of Neurology Grand Rounds.
March 23, 2000. 9. Parkinson’s Disease Clinical Correlation: From Neuroscience to Clinical Care. Course Director: Dr.
Nolan, Department of Anatomy. April 13, 2000. 10. Scientific and Societal Issues Regarding Parkinson’s Disease. Biomedical Aging Course. Course
Director: Dr. David Morgan., Department of Pharmacology. November 29, 2001.
54
TELECONFERENCES Rational Use of Combination Therapy for Parkinson’s Disease. A Group discussion for Neurologists.
May 19, 1994 October 3, 1994 October 19, 1994 October 25, 1994 November 15, 1994 April 26, 1995
Treatment Strategies in Parkinson’s Disease. A Seminar for Primary Care Physicians.
June 6, 1994 February 21, 1995 October 3, 1995
June 8, 1994 April 3, 1995 October 4. 1995 June 9, 1994 April 4, 1995 October 16, 1995 August 2, 1994 April 5, 1995 October 17, 1995 August 4, 1994 May 22, 1995 October 18, 1995 September 6, 1994 May 24, 1995 November 13, 1995 September 7, 1994 August 21, 1995 November 15, 1995 September 8, 1994 August 22, 1995 December 13, 1995 October 4, 1994 August 23, 1995 December 18, 1995 October 5, 1994 August 28, 1995 December 19, 1995 November 29, 1994 August 29, 1995 December 20, 1995 November 30, 1994 August 31, 1995 December 21, 1995 July 18, 1994 October 2, 1995 New medications for Parkinson’s disease: Dopamine agonists and COMT inhibitors. April 4, 1997.
55
Tolcapone (Tasmar) for the treatment of Parkinson’s disease (Roche):
September 29, 1998
October 22,1998
October 23,1998
December 15, 1998
Neuroprotection in Parkinson’s disease
3/22/99
Tolcapone and Hepatotoxicity
5/6/99
6/24/99
7/1/99
Essential Tremor Teleconference
7/6/99
7/7/99
Entacapone and Continuous Dopaminergic Stimulation
10/16/2001
Levodopa/carbidopa/entacapone Combination Therapy
04/15/03
Clinical Update on modafinil (Provigil)
04/15/03 04/24/03 04/30/03 05/20/03 05/27/03 05/29/03 06/10/03 06/18/03 06/30/03 07/15/03
56
MEDIA APPEARANCES 1. WTMT channel 32, “Senior Connections” television interview. Signs and symptoms of Parkinson’s
disease. October 4, 1994. 2. WTMP radio interview. Parkinson’s disease - New treatments and advances. November 17, 1994 3. WFLA channel 8 television interview. Chronic thalamic stimulation for tremor. December 9, 1994. 4. NBC TV national news affiliates, WFLA channel 8. Tolcapone clinical trials in Parkinson’s disease.
February 13, 1995. 5. WFLA channel 8 television interview. New treatments and clinical trials for Parkinson’s disease. June
14, 1995. 6. WTVT channel 13 television interview. “Good Morning Tampa Bay.” Janet Reno and Parkinson’s
disease. November 22, 1995. 7. America’s Health Network (national cable network - two hour live interview and patient calls).
Parkinson’s disease. November 17, 1996. 8. CITV local cable channel 20. Parkinson’s Disease. Half hour interview. February 3, 7, 10, 14, 17,
1998. 9. Healthcare, Medicare, and You. Parkinson’s Disease. WBSV. Sarasota, Florida. February 23, 1998. 10. Huntington’s disease cell transplantation. Bay News Nine. June 23, 1998. 11. Deep brain stimulation for the treatment of Parkinson’s disease. WFLA channel 8 television
interview. November 17, 1998. 12. Parkinson’s disease in young adults (Michael J. Fox). Channel 28 television interview. December 17,
1998. 13. Botulinum toxin therapy. Channel 13 (Fox News). March 1, 1999. 14. Parkinson’s disease research. Good Day Tampa Bay. Channel 13 (Fox) interview. March 16, 1999. 15. Neurotransplantation for Parkinson’s disease. Channel 28 (ABC) interview. March 17, 1999. 16. Parkinson’s Disease. Towards a Cure. Healthtalk Interview. KNOT Radio. Prescott, Arizona.
February 7, 2000. 17. Parkinson's Disease Questions and Answers. Radio Interview. WDIS Boston, Massachusetts. June
29, 2000 18. Parkinson’s Disease Questions and Answers. Radio Interview. WSAR Sommerset, Massachusetts.
June 30, 2000.
57
19. Parkinson's Disease Study Drug, Rasagiline, Question and Answers. Bay News 9, Tampa, FL. August 24,2001
20. Parkinson’s Disease Questions and Answers. Television Interview. WTBS Channel 10, Tampa, FL.
September 4, 2001 21. Parkinson’s Disease Questions and Answers. Television Interview, Modern Medicine. Channel 67,
New Port Ritchey, FL. September 26, 2001. 22. Parkinson's Disease Questions and Answers. The Tampa Tribune, Tampa, FL October 3, 2001 23. Parkinson’s Disease – Slowing disease progression – Channel 8, Tampa, FL March 11, 2002 24. Retinal Cell Transplantation – Fox 13, Tampa, FL April 2, 2002 25. Retinal Cell Transplantation – Channel 28 Tampa, FL April 3, 2002 26. Florida Coalition to Cure Parkinson’s Disease – Channel 13, Tampa, FL April 12, 2002 27. Florida Coalition to Cure Parkinson’s Disease – St. Pete Times (Newspaper), April 12, 2002 28. Florida Coalition to Cure Parkinson’s Disease – WUSF, Tampa, FL April 12, 2002 29. Florida Coalition to Cure Parkinson’s Disease – Channel 8, Tampa, FL April 12,2002 30. Florida Coalition to Cure Parkinson’s Disease – Bay News 9 , Tampa, FL April 12,2002 31. Coenzyme Q10 – television interview with Linda Hurtado, local ABC affiliate. October 15, 2002 32. The future of Parkinson’s Disease (Florida COALITION to Cure Parkinson’s Disease) - radio
interview. WUSF FM. April 15, 2003 33. Challenges of Treating Parkinson’s Disease (Florida COALITION to Cure Parkinson’s Disease) –
television interview. Fox 13 with Frank Robertson. April 25, 2003. 34. Parkinson’s Disease: Symptoms and Treatment. Radio Interview. WLVU 1040 AM. April 26, 2003
34. The future of Parkinson’s Disease (Florida COALITION to Cure Parkinson’s Disease) - radio
interview. WUSF FM. April 15, 2003 35. The future of Parkinson’s Disease (Florida COALITION to Cure Parkinson’s Disease) – television
interview. BayNews 9. April 26, 2003. 36. Possible bad case of Botox in West Palm Beach – Fox 13 News. November 30, 2004.
58
MULTI-CENTER STUDY PARTICIPATION “A Double-blind Study of Two Dose Levels of CQA 206-291 Versus Placebo in the Treatment of Parkinson’s Disease” Sandoz (1990-1991) Co-Investigator “A Triple-Blind, Randomized Parallel Study Comparing Sinemet CR (50/200) with Sinemet 25/100 in Parkinson’s Disease for Patients on No Prior Levodopa Therapy” Merck, Sharp and Dohme (1989-1995 ) Investigator “Prospective Single-Blind, Double-Observer, Randomized Study Comparing Treatment with Levodopa Plus Deprenyl, Levodopa Plus Deprenyl Placebo, Parlodel Plus Deprenyl and Parlodel Plus Deprenyl Placebo in Patients with Parkinson’s Disease” (1989-1994) Investigator “Determination of the Dose Response and Plasma Concentration Response of Lazabemide (RO19-6327) In Delaying Time Until Treatment with Levodopa/Carbidopa is Required in Parkinson’s Disease Patients” Hoffmann-La Roche (Parkinson Study Group) (1992-1994) Investigator “A Phase II-III Prospective, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Safety and Efficacy Study of Recombinant, Human Ciliary Neurotrophic Factor (rHCNTF) in Patients with Amyotrophic Lateral Sclerosis” Regeneron (1992-1994) Investigator “Ropinirole Versus Placebo as an Adjunct to Levodopa in the Treatment of Parkinson’s Disease” SmithKline Beecham (1993- 1996) Investigator “Double-Blind, Placebo-Controlled, Parallel-group Comparison to Assess the Safety, Tolerance, and Efficacy of Pramipexole in Early Parkinson’s Disease (Part I) and to Assess Long Term Safety with Open-Label Pramipexole (Part II)” UpJohn Laboratories (1993- 1999) Investigator “Double-Blind, Placebo-Controlled, Parallel-group Comparison to Assess the Safety, Tolerance, and Efficacy of Pramipexole in Advanced Parkinson’s Disease (0679) and to Assess Long Term Safety with Open-Label Pramipexole (0979)” Boehringer Ingelheim (1993- 1997) Investigator “Clinical Investigation of Deep Brain Stimulation for Treatment of Tremor Using the Medtronic Model 3382 DBS Lead and Itrell II System” Medtronics (1993-2000) Investigator “Parallel Group, Placebo-controlled, Dose-response, Tolerability, Safety and Efficacy Study of Pramipexole in Early Parkinson’s Disease (STEP-UP)”
59
Upjohn (Parkinson Study Group) (1994- 1995) Investigator “Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism (DATATOP Extension Studies)” National Institutes of Health/University of Rochester/Somerset Pharmaceuticals (1993-1995) Investigator “A Pilot Evaluation of the Tolerability, Safety and Efficacy of Tolcapone alone, and in combination with Selegiline in Untreated Parkinson’s Disease Patients” Hoffmann-La Roche (1995) Investigator “A Double-Blind, Placebo-Controlled, Parallel Groups, Multicenter Evaluation of the Marketing Formulation of Tolcapone When Given Together with Sinemet (levodopa/carbidopa) to Parkinson’s Disease Patients Who Exhibit End-Of-Dose Wearing-Off” Hoffmann-La Roche (1995) Investigator “A Parallel Group, Placebo-Controlled, Dose Ranging Study of Eldepryl 2.5 mg Tablets in Doses of 2.5, 5, 7.5 and 10 mg QD versus Placebo in the Treatment of Patients with Parkinson’s Disease” Somerset Pharmaceuticals (1995) Investigator “A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Intramuscular BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Cervical Dystonia” Allergan Pharmaceuticals (1995-1997) Investigator “Tolerability of TVP-1012, a Novel MAO-B Inhibitor in Parkinsonian Patients” Lemmon/Teva (1996-1997) Investigator “Observer-blind, Randomized, Parallel-group Comparison of tolcapone and pergolide given in combination with Madopar (Levodopa/Benserazide) or Sinemet (levodopa/carbidopa) in Parkinsonian patients who exhibit end-of-dose “wearing-off,” with open-label extension of tolcapone” Hoffmann La Roche (1996-1997) Investigator “Open-Label Study of Safety and Tolerability of Transdermal Selegiline in Mild to Moderate Parkinson’s Disease.” Somerset Pharmaceuticals Inc. (1996-1997) Investigator “A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study for the Safety, Tolerability and Efficacy of Daily, Oral Doses of Remacemide Hydrochloride in Patients with Early Parkinson’s Disease.” (RAMP) Parkinson Study Group/Astra Merck, Inc. (1997-1998) Investigator
60
“Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Clinical Trial for the Efficacy, Tolerability and Safety of Two Doses of Rasagiline in Early Parkinson’s Disease (PD) Patients Not Treated With Levodopa.” (TEMPO) Teva Pharmaceutical Industries, Ltd., Israel (1997-2000) Investigator “A Prospective, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Short-Term Efficacy and Safety of Entacapone Administered Together with Levodopa in Subjects with Parkinson’s Disease without Motor Fluctuations.” Sandoz Pharmaceuticals Corporation (1997-2000) Investigator “Olanzapine vs. Placebo for Treatment-Associated Psychosis in Patients with Parkinson’s Disease.” Eli Lilly and Company (1997-1998) Co-Investigator “Phase III, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of Betaseron in Patients with Secondary-Progressive Multiple Sclerosis” Berlex Laboratories (1995-2000) Co-Investigator “A Long-term, Double-Blind Comparison of Tolcapone versus Placebo Given in Combination with Levodopa/AADC-I in Delaying the Onset of Motor Fluctuations in Parkinson’s Disease Patients Naive to Levodopa Therapy.” (DORF) Hoffmann La Roche (1997-1999) Investigator “Placebo-Controlled, Double-Blind Study of the Safety, Tolerability and Efficacy of the Selegiline Transdermal System (STS) in Parkinson’s Disease Patients Experiencing Sub-Optimal Responses to Levodopa/Carbidopa.” Somerset Pharmaceuticals (1997-2000) Investigator “Co-Enzyme Q10 and Remacemide: Evaluation in Huntington’s Disease (CARE-HD).” National Institutes of Health/Huntington Study Group (HSG) (1997-2002) Investigator “Sertraline for the Treatment of Depression in Parkinson’s Disease Patients.” (1997-2000) Investigator “An Open Label, Multicenter Clinical Evaluation of the Safety of Intramuscular BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex Manufactured from Neurotoxin Complex Batch BCB2024 in the Management of Cervical Dystonia.” Allergan (1997) Investigator “A double blind, controlled, multicenter clinical trial of the safety and efficacy of transplanted fetal porcine cells in patients with Parkinson’s disease.” Diacrin/Genzyme (1998-2001)
61
Investigator “A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study for the Safety, Tolerability and Efficacy of SIB-1508Y in Parkinson’s Disease Patients who are Requiring but not Receiving Dopaminergic Therapy.” (TEST-PD) SIBIA Neurosciences, Inc. (1997-1999) Investigator “A Multicenter, Double-Blind, Parallel-Group, Placebo Controlled Study of the effect on the progression of Parkinson’s disease of Rilozole 50 mg BID or 100 mg BID for two years in 1050 patients.” Rhone-Poulenc Rorer (1998-2001) Investigator “A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study For The Safety, Tolerability And Efficacy Of Daily, Oral Doses Of Remacemide Hydrochloride In Levodopa Treated Parkinson’s Disease (PD) Subjects With Motor Fluctuations.” (REAL) Parkinson Study Group/Astra Merck, Inc. (1998-1999) Investigator “A Randomized, Double-Blind, Parallel-Group Study To Compare The Safety and Efficacy of ZYDIS Selegiline 1.25 to 2.5mg Q.D. with Placebo as an adjunct in the Management of Parkinsonian Patients being treated with Levodopa who exhibit deterioration in the quality of their response to this therapy.” Scherer DDS/Elan Pharmaceuticals (1998-2001) Investigator “Early vs. Late L-Dopa in Parkinson’s Disease (The ELLDOPA Study).” National Institutes of Health (1998-2001) Investigator “Usefulness of Tolcapone for the Treatment of Parkinson’s Disease Patients with Fluctuations and Dyskinesia” (1998-2000) “Pramipexole-Ropinirole Switching Study in Advanced Parkinson’s Disease Patients on Levodopa” SmithKline Beecham (1998-2001) Investigator “A Double-blind, multicenter, flexible dose, l-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3-D PET scanning , and B) opthalmological safety, in patients with early Parkinson’s disease” SmithKline Beecham (1999-2001) Investigator Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia” Ipsen Limited (1998-2002) Investigator “A Multicenter, Randomized, Double-blind, Parallel Group Pilot Study Comparing TV-1203/Carbidopa Dispersible Tablets with Standard Levodopa/Carbidopa Tablets in Advanced Parkinson’s Disease (PD) Patients with Response Fluctuations” Parkinson Study Group/TEVA Pharmaceuticals (1999-2002)
62
Investigator “A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel group, MultiCenter, Exploratory Study of the Safety and Efficacy of KW-6002 as Adjunctive Therapy in Patients with Parkinson’s Disease Who Have Motor Response Complications on Levodopa/Carbidopa” Kyowa Pharmaceuticals (1999-2001) Investigator “A Multicenter, Open-label, Phase III Study for the Safety, Tolerability and Clinical Effect of Rasagiline Mesylate in Patients with Parkinson’s disease” TEVA Pharmaceuticals (1999-present) Investigator “A multi-national, multi-center, double-blind, placebo controlled study to evaluate the efficacy, tolerability and safety of glatiramer acetate for injection in Primary Progressive Multiple Sclerosis patients Teva Marion Partners (1999-2003) Co-Investigator “Parkinson’s Research: The Organized Genetics Initiative (PROGENI)” Parkinson Study Group/National Institutes of Health (1999-present) Investigator “Pilot Huntington At Risk Observational Study (PHAROS)” Huntington Study Group/National Institutes of Health (1999-present) Investigator “A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel group, MultiCenter, Exploratory Study of the Safety and Efficacy of KW-6002 as Adjunctive Therapy in Patients with Parkinson's Disease Who Have Motor Response Complications on Levodopa/Carbidopa” Kyowa Pharmaceuticals (1999 –2001) Investigator “A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Escalating Transdermal Doses of SPM 962 in Subjects with Early Stage Parkinson’s Disease” Schwarz Pharma/Parkinson Study Group (1999 –2001) Investigator “Randomized, Double-blind, Placebo-controlled, Parellel-group, 6-month Safety, Efficacy, and Neuroimaging Trial of AMG-474-00 in the Treatment of Patients with Parkinson’s Disease” Amgen, Inc. (2000-2001) Investigator “An Open-label Extension Study of Remacemide Hydrochloride 300 mg bid in Subjects with Huntington’s Disease” (2000-2002) Investigator
63
“Entacapone to Tolcapone Switch Study: To Determine Whether Tolcapone Can Improve Patients Receiving Optomal Treatment with Entacapone” (2000-2002) Investigator “An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of Off Episodes in Patients with On-Off or Wearing-Off Effects Associated with Late-Stage Parkinson’s Disease” Mylan Pharmaceuticals (2000 – 2003) Investigator “A Randomized, Controlled, Multicenter Clinical Study of the Efficacy and Safety of Fetal Porcine Neuronal Cells (NeuroCell-PD) Implanted Into Patients with Advanced Parkinson's Disease Compared to Standard Anti-Parkinson Medication Therapy Alone” Diacrin/Genzyme (2000 – present) Investigator “A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group Study Comparing TV-1203/Carbidopa Dispersible Tablets with Levodopa/Carbidopa Tablets in Advanced Parkinson’s Disease (PD) Patients with Motor Fluctuations” TEVA Pharmaceuticals (2000 – 2002) Investigator “A Multicenter, US and Canada, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study, for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson’s Disease with Motor Fluctuations.” TEVA Pharmaceuticals (2000-2002) Investigator “A Multicenter, Double-Blind, Placebo-Controlled Study of the Tolerability and Effect of Entacapone in Parkinson’s Subjects with End-of-Dose Wearing Off Symptoms Occurring No Earlier than 4 Hours After Their Most Recent Levodopa/Carbidopa Dose” Novartis (2001 – 2002) Investigator “An Open Label Safety and Immunogenicity Study of MYOBLOC™ (Neurobloc®; Botulinum Toxin Type B) Injectable Solution in Patients with Cervical Dystonia” Elan Pharmaceuticals (2001-present) Investigator “Observational Study of BOTOX® Use in Cervical Dystonia” Allergan (2001- 2005) Investigator “A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of ropinirole controlled-release (CR) in Parkinson’s Disease Patients not receiving other dopaminergic therapies “ Skye-Pharma (2001-2002) Investigator
64
“A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in the Treatment of Essential Tremor “ Ortho-McNeil (2001-2004) Investigator “A non-interventional follow-up study to observe the long term outcome of Parkinson’s disease in patients who completed Study SK&F 101468/056 or Study SK&F 101468125” SmithKline Beecham Pharmaceuticals (2001-2003) Investigator “A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson’s Disease (PD) Patients with Motor Fluctuations Treated with Chronic Levodopa/Carbidopa Therapy TEVA Neuroscience, LLC (2001-present)” Investigator “A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of Efficacy of Two Doses of KW-6002 as Treatment for Parkinson’s Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy Kyowa Pharmaceuticals (2002- 2003) Investigator “A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients with Early Parkinson’s Disease (PRECEPT)” Cephalon, Inc./Parkinson Study Group (2002-present ) Investigator “Double-Blind, randomized, placebo-controlled, multicenter study with two step group sequential design in patients with advanced idiopathic Parkinson’s disease to evaluate over twelve months the safety, tolerability and efficacy of 650,000 cultured retinal pigment epithelial cells attached to gelatin microcarriers (Spheramine®) implanted bilaterally (325,000 each side) into the postcommissural putamen” Berlex Labs (2002-present) Investigator “A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients with Parkinson’s Disease Who Completed the Previous Phase 2 Ropinirole CR Study-167” SkyePharma Inc. (2002-present) Investigator “A 12 Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS).” GlaxoSmithKline (2002) Investigator “A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Suffering from Restless Legs Syndrome (RLS)” GlaxoSmithKline (2002-2004) Investigator
65
“An Open-Label, Randomized, Two Part Study to Investigate the Relative Bioavailability of Ropinirole CR and IR Formulations and the Effects of Food on the Pharmakinetics of Ropinirole CR Formulations in Early Stage Parkinson’s Disease Patients” SmithKline Beecham (2003-2004) Investigator “A Long-Term Multicenter, Open-Label, Safety Study with a Flexible Dose Range of KW-6002 as Treatment for Parkinson’s Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy” Kyowa Pharmaceuticals (2003-2004) Investigator “A 4-week, Multicenter, Open-label, Single Arm Study Assessing Tolerability of Triple Combination (TC) in Parkinson’s Disease Patients Who Experience End of Dose Wearing Off With Levodopa” Novartis (2003-2004) Investigator “A Multicenter, Double-Blind, Futility Study of Minocycline and Creatine in subjects with early untreated Parkinson's Disease (PD).” NIH, National Institute of Neurological Disorders and Stroke (NINDS) (2003-present) Investigator “A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Efficacy and Safety of Sumanirole in Patients with Idiopathic Restless Legs Syndrome” Pharmacia (2003-2004) Investigator “A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson’s Disease Patients (Study for Proof Concept in Early Parkinson’s Disease of a Triple Reuptake Inhibitor, NS 2330/SCEPTRE)” Boehringer Ingelheim (2003-present) Investigator “A 12 Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS)” GlaxoSmithKline (2003-present) Investigator “A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of Six Months Treatment with Ropinirole CR as Adjunctive Therapy in Patients with Parkinson’s Disease who are not optimally controlled on L-Dopa” GlaxoSmithKline (2003-present) Investigator An Open-Label Extension Study with REQUIP (ropinirole) CR for subjects from studies 101468/165, 101468/168 and 01468/169 (2004-present) Phase II, Multi-Center Placebo-Controlled, Double-Blind Trial, of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease. ACADIA Pharmaceuticals Inc. (2004-present)
66
Investigator A Multicenter, Double-Blind, Pilot Study of CoQ10 and GPI 1485 in subjects with early untreated Parkinson’s Disease (PD), National Institute of Neurological Disorders and Stroke (NINDS) (2004-present) Investigator A two year Phase IIIb randomised, multicenter, double-blind, Sinemet-controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson’s disease subjects. GlaxoSmithKline (2003-present) Investigator A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson’s Disease Hines VA/NINDS (2004-present) Investigator Evaluation of the Efficacy and Safety of ALTROPANE for differentiating Parkinsonian Syndromes from Non-Parkinsonian Syndromes in Patients with Tremors Boston Life Sciences, Inc. (2004-present) Investigator A 12 Week, Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of a 20 mg/d Oral Dose of KW-6002 (Istradefylline) As Treatment for Parkinson’s Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy Kyowa Pharmaceutical, Inc. (2004-present) Investigator
67
Single Site Studies “Central and Peripheral Pharmacokinetics and Behavioral Effects of Levodopa Administered as Standard Sinemet or Sinemet CR in Patients with Advanced Parkinson’s Disease” Dupont Merck Pharmaceuticals (1992-1996 ) Investigator “Pharmacokinetics of Sinemet versus Sinemet Plus Deprenyl in Patients with Parkinson’s Disease” (1993-1996 ) Investigator “Transplantation of Human Embryonic Striatal Tissue as a Treatment for Huntington’s Disease” (1996-) Investigator “A Pilot Study to Investigate the Causes of Fatigue in Parkinson’s Disease with Emphasis on the Role of Sleep Disorders, Followed by an Open-Label Trial of Modafinil in Patients Lacking a Defined Cause for Fatigue” (2000 -) Investigator “Glutathione (GSH) In The Treatment of Parkinson’s Disease” Wellness Health Pharmaceuticals (2002-present) Investigator Other Grants NINDS PD Neuroprotection Clinical Trial: Clinical Centers. Hauser RA, site PI. (Grant #1 U10 NS4-4425-01) $532,875. (2002-2007) “Parkinson’s Research: The Organized Genetics Initiative (PROGENI)” $85,455 (1999-2009) Grant from Wellness Pharmaceutical for Independently run trial: Glutathione (GSH) in the Treatment of Parkinson’s Disease $25,000 (2003-2008) Grant from the National Parkinson’s Foundation: NPF Care Centers of Florida $50,000/year (2001-2005) A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson’s Disease. $16,417,508 (2004-2010)
68
UNIVERSITY AND COMMUNITY SERVICE Departmental Representative, United Way Fund 1990 Medical Student Applicant Interviewer 1990-1992 Member, Professional Advisory Committee 1990-1995 National Multiple Sclerosis Society, Florida Gulf Coast Chapter Member, LCME Committee 1990-1992 On General Facilities and the Library University of South Florida College of Medicine Department of Neurology Faculty Council Representative 1992-1996 University of South Florida College of Medicine Department of Neurology Residency Committee 1994-1997 University of South Florida College of Medicine Department of Neurology Research and Scholarly Productivity Committee 1994-1997 University of South Florida College of Medicine Department of Neurology Resident Research Committee 1994-1997 Tampa General Hospital Neuroscience MDC Advisory Committee 1994-1995 University of South Florida Physicians Group Physician Policies, Credentialing, and Peer Review Project Team 1995 University of South Florida Health Sciences Research Committee 1995-1997 University of South Florida Institute on Aging Research Committee 1995-1997 Tampa General Hospital 1998-2000 Neuroscience CPIT
69
Co-Chairman 1998 - 2000 Dean’s Green and Gold Blue Ribbon Committee on Research University of South Florida College of Medicine Member, Committee on Committees 1998-1999 University of South Florida College of Medicine Member, Bylaws Committee 1998-1999 University of South Florida College of Medicine Member, Executive Committee 1999-2002 Department of Neurology University of South Florida College of Medicine Member, Neurosurgry Chair Search Committee 1999-2002 University of South Florida College of Medicine Member, Ad Hoc Interdisciplinary Committee 2000-2001 Tampa General Hospital Member, Curriculum Development Working Group 2000-2001 University of South Florida College of Medicine Member, IRB Data Safety Monitoring Board 2000-2001 University of South Florida College of Medicine Member, Managed Care Committee 2001-present University of South Florida College of Medicine Member, Billing and Integrity Compliance Committee 2002-present University of South Florida College of Medicine University of South Florida College of Medicine representative 2002-present Faculty Senate University of South Florida Member, USF Faculty Senate committee on committees 2002- present
70
ADDITIONAL UNIVERSITY TEACHING ACTIVITIES Director, Movement Disorder Fellowship 1994-2002 Director, Fourth Year Medical Student Neurology Rotation 1998-2001 Summer Research Fellowship in Neurology 1998 Catherine Wendell ADDITIONAL NATIONAL TEACHING ACTIVITIES Chairman, Newsletter Casexchange Series: Focus on 1998 Parkinson’s Disease Chairman, Newsletter Casexchange Series: Focus on 2000 Parkinson’s Disease CONTINUING EDUCATION Advanced Trauma Life Support – 1983
Advanced Cardiac Life Support – 1985 Armed Forces Institute of Pathology Neuropathology Course - 1985 Armed Forces Institute of Pathology Neuropathology Course - 1987 Armed Forces Institute of Pathology Neuroradiology Course - 1987 Electromyography Update Medical College of Virginia - 1987 Update on Infection Eastern Virginia School of Medicine - 1987 American Academy of Neurology Annual Meeting Cincinnati, Ohio - 1988 American Society of Neuroimaging Neuroimaging Course - Orlando, Florida 1989 American Academy of Neurology Annual Meeting Chicago, Illinois - 1989 Risk Management Seminar
71
University of South Florida, Tampa, Florida - 1989 Update on AIDS University of South Florida, Tampa, Florida - 1989 Update on the Management of Seizure Disorders The Epilepsy Foundation, Orlando, Florida - 1989 American Society of Neuroimaging Neuroimaging Course - San Diego, California-1990 First International Congress of Movement Disorders Washington, D.C.- April 23-28, 1990 Parkinson’s Disease and Other Movement Disorders, Fourth Annual Symposium. Keystone, Colorado. February 27-March 1,1991 (12 hrs. CME) Medical Risk Management, Tampa, Florida, April 6, 1991. (5 hrs. CME) Epilepsy: Current Therapy and New Considerations. Hilton Head, South Carolina. May 24-26, 1991. (8.5 hours CME). HIV/AIDS Update. University of South Florida, Tampa, Florida. September 4, 1991. (1 Hr. CME). AIDS Update. Sheraton Grand Hotel. Tampa, Florida. September 10, 1991. (1 Hr. CME). Managing Movement Disorders in the 1990’s. San Diego, California. May 2, 1992. (3 Hrs. CME). American Academy of Neurology. 44th Annual Meeting. San Diego, California. May 3-9, 1992. (63 Hrs. CME). The American Neurological Association. Toronto, Ontario, Canada. October 18-21, 1992. (17 CME Hours). American Society of Neuroimaging, 16th Annual Meeting. Orlando, Florida, February 2-5, 1993. (15.5 CME Hours). Second Annual Headache Symposium. Tampa Marriott Westshore, Tampa, FL, April 23, 1994. (8 CME Hours). American Academy Of Neurology. 46th Annual Meeting. Washington, D.C. April 29-May 8, 1994. (30 CME Hours). American Neurological Association. 119th Annual Meeting. 8th Annual PSG/MODIS Symposia.
72
San Francisco, California. October 8-12, 1994. (15 CME Hours) Third International Congress of Movement Disorders. Orlando, Florida. November 7-11, 1994. (25 CME Hours) Botulinum Toxin Seminar. Medical College of Georgia. Augusta, Georgia. September 21-22, 1994. Eighth Annual PSG Meeting. San Diego, California. February 23-February 25, 1995.
American Society of Neural Transplantation. Second Annual Meeting. Clearwater, Florida. April 28-29, 1995.
47th Annual Meeting of the American Academy of Neurology. Seattle, Washington. May 7-May 13, 1995. (19.5 CME Hours)
Domestic Violence Tampa General Healthcare. Tampa, Florida. September 21, 1995. (1.0 CME Hours)
Worker’s Compensation Certified Training Course for Physicians. Tampa General Healthcare Tampa, Florida. September 23, 1995. (5.0 CME Hours)
48th Annual Meeting of the American Academy of Neurology. San Francisco, California. March 23-30, 1996. (15.0 CME Hours) American Society of Neural Transplantation, third annual conference. Clearwater, Florida, April 25, 1996. Fourth International Congress of Movement Disorders. Vienna, Austria, June 17-21, 1996.
49th Annual Meeting of the American Academy of Neurology. Boston, MA. April 12-17, 1997.
50th Annual Meeting of the American Academy of Neurology. Minneapolis, Minnesota. March 26-February 1, 1998. MBA Program for Physicians. University of South Florida. May 24 – September 18, 1998. (50 CME Hours) MBA Program for Physicians. University of South Florida. October 1, 1998 – November 1, 1999. (50 CME Hours) 1st Annual Compliance Training for Faculty, Residents and Staff. University of South Florida. September 2, 1998. (1.0 CME Hours) Fifth International Congress of Movement Disorders. New York, NY. October 8-14, 1998. Neurology Grand Rounds. University of South Florida. January 1 – June 30, 1999. (4.0 CME Hours)
73
51st Annual Meeting of the American Academy of Neurology. Toronto, Ontario, Canada. April 18-22, 1999.
Sixth Annual Conference of the American Society for Neural Transplantation and Repair. Clearwater, Florida. April 30, 1999. HIV/AIDA Update. Domestic Violence Update. Tampa General Healthcare. September 8, 1999. (2.0 CME Hours) Research Compliance Conference. University of South Florida. October 9, 1999. (5.0 CME Hours) International Conference 1999: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Orlando, Florida. November 15-19, 1999. American Academy of Neurology 52nd Annual Meeting. San Diego, California. April 29 – May 6, 2000. (9.5 CME Hours). American Academy of Neurology 53rd Annual Meeting. Philadelphia, Pennsylvania. May 6-12, 2001. American Academy of Neurology 54th Annual Meeting. Denver, Colorado. April 13-20, 2002. 7th International Congress of Parkinson’s Disease and Movement Disorders. Miami, FL. November 10-14, 2002. ADVISORY BOARDS AND CONSULTANT MEETINGS Tasmar Advisory Board meeting. Roche Laboratories. Vienna, VA. June 19,1997. Entacapone Cosultants meeting. Novartis. Buenos Aires, Argentina. September 14-15, 1997. Parkinson’s Disease/Ropinirole Neurology Advisory Board Meeting. SmithKline Beecham. Orlando, FL. November 21-23, 1997. Eldepryl Advisory Board Meeting. Watson Laboratories. New York, New York. March 13, 1998. Botox Advisory Meeting. Science and Technology Update. Scottsdale, Arizona. March 21-22. Novartis Advisory Board Meeting. Minneapolis, Minnesota. April 24-25, 1998. Roche Consultant’s Meeting. Minneapolis, Minnesota. April 30, 1998. Teva Consultant’s Meeting. New York, NY. July 17, 1998. SmithKline Advisory Board Meeting . Palm Springs, California. November 13-15, 1998. Roche Advisory Board Meeting. New York, NY. November 23, 1998. Athena Essential Tremor Advisory Board. San Francisco, California. March 3, 1999.
74
Elan botulinum toxin Advisory Board. Napa Valley, California. July 30, 1999. Elan Essential Tremor Advisory Board. New York, New York. August 16, 1999. Novartis Comtan National Advisory Summit. Hamilton, Bermuda. September 14-16, 1999. AstraZeneca Huntington’s Disease Advisory Board. Arlington, Virginia. September 24-25, 1999. AstraZeneca Parkinson’s Disease Advisory Board. Toronto, Canada. October 15-16, 1999. NeuroCell-PD Advisory Meeting. Boston, Massachusetts. January 11, 2000. Botox Advisory Board (Allergan). Irvine, California. April 28, 2000. National Requip Advisory Board (SmithKline Beechum). San Diego, California. April 29, 2000. Elan Pharmaceuticals Neurology Advisory Board. San Diego, California. May 26, 2000. Solvay Pharmaceuticals SLV308 International Steeing Committee. Amsterdam, The Netherlands. September 29, 2000. Aventis Expert Advisory Panel (Riluzole). Rio Grande, Puerto Rico. December 1-3, 2000. Pharmacia US Advisory Board (Mirapex). Miami, Florida. January 10-12, 2001. Sarizotan International Advisory Board (Merck KgaA). New York, New York. March 8, 2001. Glaxo-SmithKline National Advisory Board (Requip). Charleston, South Carolina. March 23-24, 2001 Pharmacia Global Thought Leadership Summit. Istanbul, Turkey. April 26-29, 2001. Glaxo-SmithKline National Advisory Board (Requip). Sonoma, California. October 12-14, 2001. Elan Regional Advisory Board Meeting (Myobloc). Atlanta, Georgia. November 17, 2001. Glaxo-SmithKline National Advisory Board (Requip). Keystone, Colorado. February 2, 2002. Allergan National Advisory Board (Botox). Atlanta, Georgia. April 5, 2002. Pharmacia National Advisory Board (Mirapex). Amelia Island, FL. June 21, 2002. Pharmacia. National Advisory Board (Mirapex). New York, NY. September 19, 2002. Glaxo-SmithKline. Clinical Consultants meeting (Requip CR). Philadelphia, PA. September 24, 2002. Teva Neuroscience Key Investigator meeting (Rasagiline). Chicago, IL. October 2, 2002. Novartis. End of dose wearing off (EODWO) working group meeting. New York, NY. October 3, 2002. Geron Consultancy Meeting. San Francisco, CA. November 15, 2002.
75
Cephalon. Modafinil and PD Advisory Meeting. New Orleans, Louisiana. January 24, 2003. Glaxo-SmithKline. National Advisory Board. New Orleans, Louisiana. January 25, 2003. Novartis. TCH 346 Advisory Board Meeting. Short Hills, New Jersey. April 28, 2003. SPONSORED MEETINGS
76
Tasmar Speaker’s Bureau Meeting. Tuscon, Arizona. March 6, 1998. Glaxo-SmithKline. Expert Forum Meeting. Dopamine Agonists and Neuroprotection in Parkinson’s Disease. Geneva, Switzerland. June 8-9,2001. Glaxo-SmithKline. Faculty development meeting. Chicago, Illinois, June 22-24,2001. Novartis. Extend the Reach Program. Presenter - Case Studies. Orlando, Florida. June 15-16, 2001. Novartis. Neurology Network Initiative: An educational Outreach Program. Presenter. Orlando, Florida. August 25, 2001. Novartis. Speaker Development Program. Miami, Florida. December 8, 2001. Novartis. Speaker Development Program. Las Vegas, Nevada. February 23, 2002. Pharmacia. International Neuroscience Conference. Budapest, Hungary. September 13, 2002. Allergan. SCIENCE – Summit Conference and Interdisciplinary Effort for Neurotoxin Comprehensive Education. San Juan, Peurto Rico. December 6-7, 2002. Novartis. End-of-dose wearing off (EODWO) working group meeting. Gstaad, Switzerland. February 19, 2003. Novartis. End-of-dose wearing off (EODWO) working group meeting. London, UK. March 5, 2003. RECENT PROFESSIONAL MEETINGS 12th Annual Parkinson’s Disease Study Group. Las Vegas, Nevada. March 8-11, 1999. Sixth National Parkinson Foundation International Symposium. Miami, Florida. October 22-23.
77
Neural Reconstruction Study Group, Inaugural Meeting. Miami, Florida. October 25, 1999. 7th Annual Huntington’s Disease Study Group. Palm Beach, Florida. November 4-6, 1999. 13th Annual Parkinson's Disease Study Group, Stuart, Florida. May 18-21, 2000. Huntington’s Disease Society of America Coalition for the Cure Research Conference. La Jolla, California. October 24-26. HSG 8th Annual Meeting. La Jolla, California. October 28, 2000. First Annual Meeting of the Florida Movement Disorders Society. Jacksonville, Florida. November 3-2, 2000. 53rd Annual Meeting of the American Academy of Neurology. Philadelphia, Pennsylvania. May 5-10, 2001. 14th Annual Parkinson’s Disease Study Group meeting. Key Biscayne, FL. May 17-19, 2001. Huntington’s Disease Society of America 2nd Annual Center of Excellence Conference. Atlanta, Georgia. September 15-16, 2001. AliProject Executive Council Meeting. Chicago, Illinois. October 1, 2001. Huntington Study Group 9th Annual Meeting. Toronto, Canada. November 4-5, 2001. National Parkinson Symposium 7th Annual Meeting. San Diego, California. November 8-9, 2001. 54th Annual Meeting of the American Academy of Neurology. Denver, Colorado. April 14-20, 2002. 15th Annual Parkinson’s Disease Study Group meeting. Coronado, California. May 16-19, 2002.